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1. Introduction: 
1.1 The Prostate (Anatomy and function) 
A firm, partly muscular, partly glandular body, the prostate is situated at the base of the male 
urethra; the average prostate weighs 18 g; measures 3 cm in length, 4 cm in width and 2 cm in 
depth; and is traversed by the prostatic urethra. Although ovoid, the prostate is referred to as 
having anterior, posterior and lateral surfaces, with a broad base superiorly that continues at 
the base of the bladder and a narrowed apex inferiorly at the urogenital diaphragm (the 
striated urethral sphincter). Its capsule is composed of collagen, elastin and abundant smooth 
muscle [1]. The prostate is composed of approximately 30% fibromuscular stroma and 70% 
glandular elements. The urethra does not run straight through the middle of the gland, but 
rather takes a curved course, running anteriorly as it proceeds from proximal to distal, in such 
a way that it ends up close to the prostate’s anterior surface [2]. In the past, the prostate was 
described as having two lobes, with each lobe having its own ducts and in 1906, Howe 
described a middle (or median) lobe. This lobar concept was replaced in 1981 by McNeal 
with his concentric zones concept [3].  
The transition zone, which accounts for 5–10% of the glandular tissue of the prostate, 
commonly gives rise to benign prostatic hypertrophy, which expands to compress the 
fibromuscular band into a capsule seen at enucleation of an adenoma. About 20% of prostate 
adenocarcinomas originate in this zone. The peripheral zone forms the bulk of the prostatic 
glandular tissue (70%) and covers the posterior and lateral aspects of the gland. About 70% 
percent of all prostatic cancers emerge from this zone and it is the zone most commonly 
affected by chronic prostatitis. The ducts of the central zone run circumferentially around the 
openings of the ejaculatory ducts and expand in a cone-like shape around the ejaculatory 
ducts to the base of the bladder. This zone constitutes 25% of the glandular tissue of the 
prostate and only 1% to 5% of adenocarcinomas arise in the central zone, although it may be 
infiltrated by cancers from adjacent zones [4]. Up to one third of the prostatic mass may be 
attributed to the non-glandular anterior fibromuscular stroma. This region normally extends 
from the bladder neck to the striated sphincter, although considerable portions of it may be 
replaced by glandular tissue in the adenomatous enlargement of the prostate [4]. 
The arterial supply of the prostate comes from the inferior vesical artery, the venous drainage 
of the prostate merges and runs through the periprostatic plexus and is drained into the 
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internal iliac vein, the lymphatic drainage runs primarily towards the obturator and the 
internal iliac nodes; moreover, two neurovascular bundles are located on the postero-lateral 
side adjacent to the gland and form the superior and inferior pedicles on either side [2,4]. 
 
The function of the prostate is to secrete a slightly alkaline fluid, milky or white in 
appearance, which in humans usually constitutes roughly 30% of the semen volume along 
with spermatozoa and fluid of the seminal vesicle. The alkalinity of semen helps neutralize 
the acidity of the vaginal tract, thus prolonging the lifespan of the sperm. The prostatic fluid is 
expelled in the first ejaculate fractions, together with most of the spermatozoa to provide 
better motility, longer survival and better protection of the genetic material [5]. 
1.2 Prostate cancer 
1.2.1 Definition and epidemiology 
Prostate cancer (PCa) is a malignant tumor of the prostate gland, which surrounds the urethra 
just below the bladder in front of the rectum and engenders fluid components of semen. 
Almost all prostate cancers are adenocarcinomas. It is the most prevalent cancer and the third 
most common cause of death due to cancer among men in Germany and the number of new 
cases has risen steadily in recent years; in 2010 there were 65,800 newly detected cases. PCa 
is rare in people under 50 years of age. For a 35-year old man, the risk of being diagnosed 
Figure 1: Zonal anatomy of the prostate as described by J.E. McNeal (© 1990, Baylor College of Medicine.) 
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with PCa within the next ten years is lower than 0.1%, while for a 75-year old man it is 
approximately 6% [6]. 
1.2.2 Etiology 
Although little is known about the causes of PCa development and the factors that influence 
its course, the presence of clustered cases among close relatives has now adequately been 
proved as a risk factor [6]. The results of a meta-analysis show that the relative risk increases 
with the number of affected family members, the degree of their relatedness and the age at 
which they are affected [7]. 
Chronic inflammation prompting cellular hyper-proliferation to supplant damaged tissue 
contributes to the development of infection-associated cancers of the colon, esophagus, 
stomach, bladder, liver and prostate [8,9]. In 1993 a possible relationship between vasectomy 
and PCa with a relative risk of 1.6 based on two large cohort studies was suggested for the 
first time [10,11]. Recently, a pooled relative risk of 1.37 was reported in a meta-analysis, 
with a linear trend suggesting a 10% increase for each additional 10 years since vasectomy 
[12]. Cigarette smoking, high fat consumption, especially of polyunsaturated fats, obesity and 
alcohol intake are considered as further risk factors for PCa [13–15].  
1.3 Diagnosis 
1.3.1 Symptoms 
PCa rarely causes symptoms at an early stage. The presence of symptoms suggests locally 
advanced or metastatic disease. Locally advanced PCa may come with obstructive urinary 
symptoms, hematospermia or decreased ejaculate volume and rarely renal failure due to 
ureteral obstruction. Manifestations of metastatic disease include bone pain, pathologic 
fractures, anemia and lower extremity edema and less commonly, malignant retroperitoneal 
fibrosis, paraneoplastic syndromes and disseminated intravascular coagulation (DIC). Locally 
advanced and metastatic disease is less frequent due to widespread screening with prostate-
specific antigen (PSA) and/or digital rectal examination (DRE) [16]. 
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 1.3.2 Digital rectal examination.  
PCa is generally suspected on the basis of DRE and/or the level of PSA. However, conclusive 
judgment relies on the histopathological confirmation of malignancy in prostate biopsy cores 
or surgically extracted specimens [17]. PCa is detected by a suspect DRE alone, irrespective 
of the PSA level, in about 18% of all PCa patients [18]. A suspect DRE in patients with a 
PSA level of up to 2 ng/mL has a positive predictive value of 5-30% [19].  
1.3.3 Screening 
Population or mass screening is defined as systematic examination of asymptomatic men (at 
risk) with the principal goal to improve the overall health outcomes by identifying and 
treating disease at an earlier stage. However, screening is associated with many 
disadvantages, such as overdiagnosis and overtreatment. So early PSA-testing should be 
offered to men at an elevated risk of PCa., men over 50 years of age, men over 45 years of age 
and a family history of PCa and men with a PSA level of > 2 ng/mL at 60 years of age [20]. 
1.3.4 Prostatic specific antigen 
PSA belongs to the human kallikrein gene family; it is secreted in high concentrations 
(ng/mL) in the seminal fluid and circulates in bound (complexed) and unbound (free) forms 
that can be measured using assays approved by the USA Food and Drug Administration 
(FDA) [16]. High and rising PSA levels are an indicator of possible development of PCa. 
Despite this, men may harbor PCa despite having low serum PSA; this was underscored by 
Thompson in 2004 who reports that the incidence of the presence of PCa in patients with PSA 
levels between 3.1-4.0 ng/mL is 26.9% [21]. Several modifications of serum PSA value that 
may improve the specificity of PSA in the early detection of PCa have been described. They 
include: PSA density; PSA density of the transition zone; age-specific reference ran ges, PSA 
velocity and doubling time and free/total PSA ratio [16]. 
1.3.5 Transrectal ultrasound examination and prostatic biopsy 
prostate biopsies (PBs) is determined in case of a suspicious PSA level and/or a suspicious 
DRE [17]. A single increased PSA-value should not prompt an immediatebiopsy; instead the 
PSA level should be established again after a couple of weeks under cleary defined conditions 
(i.e. no ejaculation, no manipulations such as catheterization, no cystoscopy or transurethral 
resection and no urinary tract infection) in the same diagnostic laboratory and by using the 
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same method [22,23]. PBs under ultrasound guidance is considered a standard approach. 
Although in general, a transrectal access is used for most prostate biopsies, some urologists 
prefer a perineal approach (Table 1). Cancer detection rates with perineal PBs are comparable 
to those obtained with transrectal biopsies, however many studies show that the transperineal 
approach has enhanced the identification of cancers in the transition zone sometimes not 
detected by the standard transrectal PBs in high-risk PCa patients [24–26].  
1.3.6 The ANNA/C-TRUS system 
Conventional grey scale ultrasound has only limited value in PCa diagnostics. The ANNA/C-
TRUS system was developed to remedy this problem. It is based on an artificial neuronal 
network analysis (ANNA) of transrectal grey scale ultrasound pictures. The system was 
trained to identify the lesion most suspicious for PCa by coding it in different shades of 
yellow to red based on the analysis of targeted biopsies of suspicious lesions can be 
performed (Table 1) [27].  
1.3.7 HistoScanning™ 
HistoScanning is a new non-invasive tissue characterization technology based on three-
dimensional (3D) ultrasound, providing computer-aided analysis of the native ultrasound 
radiofrequency data to identify patterns in the glandular tissue in order to detect differentiated 
tissue [28]. Due to its special capacity to precisely distinguish, locate and assess the size of 
differentiated prostate tissue and augmented ultrasound analysis, it improves the interpretation 
of transrectal prostate imaging by identifying abnormal prostatic tissue (Table 1). Prostate 
HistoScanning may be used to guide clinical decisions throughout entire PCa care: detection 
and diagnosis, treatment planning, treatment guidance and post-treatment monitoring [29]. 
1.3.8 Magnetic resonance imaging (MRI) and fusion biopsy 
There is growing interest in the use of prostate magnetic resonance imaging (MRI) to 
determine who should be offered PB and how those biopsies should be taken. The aim of 
using MRI to refine the biopsy strategy is to maximize the detection of clinically significant 
PCa, while reducing the burden of biopsy for patients and the health care system [30]. MRI is 
not only capable to assess PCa functionally and morphologically, in addition, local 
preoperative staging with conventional MRI was correct in 83.9%, with a better delineation of 
the prostatic capsule and early detection of infiltration into the neurovascular bundle [31]. The 
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BiopSee® PBs system is a novel development in this field by Hadaschik, 2011, integrating 
pre-interventional MRI data with peri-interventional US for perineal PB [32]. 
1.3.9 Computed Tomography (CT) and Positron Emission Tomography (PET) 
The use of computed tomography (CT) to evaluate the local extent of disease and the 
possibility of nodal involvement is not routinely recommended due to low sensitivity; 
however, it may be used for detection of metastasis [33]. PET is a nuclear functional imaging 
technique that produces a three-dimensional image of the body and is often accomplished 
with the aid of a CT X-ray scan performed on the patient in the same session and with the 
same machine [34]. PET/CT used for the detection of lymph node (LN) involvement, bone 
metastases, local recurrence and distant metastases in cases of biochemical recurrence (BCR), 
particularly in intermediate to high-risk Pca patients, may also play a role in radiotherapy 
dose escalation or salvage therapy, particularly in salvage surgical treatment of LN metastasis 
(Table 1) [35,36]. There are many types of PCT/CT; 18F-FDG, the most commonly used 
radiopharmaceutical for PET in oncology is based on 2-[18F]fluoro-2-deoxy-d-glucose, also 
called fluorodeoxglucose or FDG and it is successfully used in many tumor types, [11C]-
Choline-PET/CT is advisable in PMR cases with PSA levels of 1 ng/mL or higher [37].  
1.3.10 Bone scans or bone scintigraphy 
Bone scintigraphy is a nuclear scanning test to find certain abnormalities in the bone. It is 
primarily used to help diagnose a number of conditions relating to bones, including cancer of 
the bone or cancers that have spread (metastasized) to the bone, especially in PCa as more 
than 90% of the patients with advanced Pca develop bone metastases [38]. The sensitivity of 
bone scintigraphy to detect bone metastasis lies at about 94.1% and specificity at 89.2% [39].  
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Table 1: Summary of sensitivity and specificity of the imaging diagnostic tools of Pca and 
metastasis. 
 Sensitivity Specificity 
TRUS  15-68% [40,41]  63-97% [40,41] 
The ANNA/C-TRUS  83% [27]  64% [27] 
HistoScanning™  82.1% [42] 
 95% [28] 
 - 
 - 
MRI 
MRI/ BiopSee® 
 54.5% [31] 
 98.5% [32] 
 - 
 - 
CT/PET 
 F-18 choline 
 11C-choline 
 F-18 choline 
 F-18 choline 
 
 79% [43] 
 80% [44] 
 83.3% [45] 
 85.2% [36] 
 
 97% [43] 
 - 
 92.3%[45] 
 18.2% [36] 
bone scintigraphy  94% [39]  89% 
1.4 Histopathology and Gleason Score 
1.4.1 Histopathology 
The vast majority of prostatic cancers are acinar adenocarcinomas. Histological variants of 
prostatic carcinoma have been variably defined. Acinar adenocarcinoma variants were defined 
in 2004 by the WHO to include atrophic, pseudohyperplastic, foamy, colloid, signet ring, 
oncocytic and lymphoepithelioma-like carcinomas. The second group of non-acinar prostatic 
carcinoma accounts for about 5–10% of carcinomas that originate in the prostate. These 
include sarcomatoid carcinoma, ductal adenocarcinoma, urothelial carcinoma, squamous and 
adenosquamous carcinoma, basal cell carcinoma and neuroendocrine tumours, specifically 
small-cell carcinoma [46].  
1.4.2 Gleason score 
The Gleason system is based on the glandular pattern of the tumor as identified at a relatively 
low magnification. Both the primary (predominant) and the secondary (second most 
prevalent) architectural patterns are identified and assigned a grade from 1 to 5, with 1 being 
the most differentiated and 5 being the least differentiated [47]. As both the primary and the 
secondary patterns affect the prognosis of PCa, there is a Gleason sum or score obtained by 
the addition of the primary and secondary grades [48]. 
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1.5 Classification and staging systems 
1.5.1 Table 2: Tumor Node Metastasis (TNM) classification of PCa [49]. 
T - Primary tumour 
TX Primary tumour cannot be assessed 
T0  No evidence of primary tumour 
T1 Clinically inapparent tumour not palpable or visible by imaging 
T1a  Tumour incidental histological finding in 5% or less of tissue resected 
T1b Tumour incidental histological finding in more than 5% of tissue resected 
T1c 
Tumour identified by needle biopsy (e.g. because of elevated prostate 
specific antigen (PSA) level) 
T2 Tumour confined within the prostate
1
 
T2a  Tumour involves one half of one lobe or less 
T2b  Tumour involves more than half of one lobe, but not both lobes 
T2c Tumour involves both lobes 
T3  Tumour extends through the prostatic capsule
2
 
T3a  
Extracapsular extension (unilateral or bilateral) including microscopic 
bladder neck involvement 
T3b  Tumour invades seminal vesicle(s) 
T4  
Tumour is fixed or invades adjacent structures other than seminal vesicles: 
external sphincter, rectum, levator muscles, and/or pelvic wall 
N - Regional lymph nodes
3
 
NX  Regional lymph nodes cannot be assessed 
N0  No regional LN metastasis 
N1  Regional LN metastasis
4
 
M - Distant metastasis
5
 
MX  Distant metastasis cannot be assessed 
M0  No distant metastasis 
M1  Distant metastasis 
M1a  Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) 
1 Tumour found in one or both lobes by needle biopsy, but not palpable or visible by imaging, is classified as T1c. 
2 Invasion into the prostatic apex, or into (but not beyond) the prostate capsule, is not classified as pT3, but as pT2. 
3 The regional lymph nodes are the nodes of the true pelvis, which essentially are the pelvic nodes below the bifurcation of 
the common iliac arteries. 
4 Laterality does not affect the N-classification 
5 When more than one site of metastasis is present, the most advanced category should be used. 
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1.5.2 Risk classification of PCa 
Table 3: EAU risk groups for BCR of localized and locally advanced Pca, 2015 [50].  
 Low-risk Intermediate-risk High-risk 
PSA level 
≤ 10 ng / mL 
and 
10 – 20 ng / mL 
and 
> 20 ng / mL 
or 
any PSA 
Gleason score 
≤ 6 
and 
7a or 7b 
Or 
> 7 
or 
any 
and 
T- stage T1a- T2a T2b T2c 
T3-4 or 
N1 
 Localised Locally advanced 
 
1.6 Treatment of localized PCa 
1.6.1 Active surveillance and watchful waiting 
Active surveillance aims to achieve correct timing for curative treatment; patients remain 
under close surveillance and are treated promptly on reaching a predefined threshold 
indicating potentially life-threatening disease, while considering the individual patient’s life 
expectancy. Watchful-waiting refers to conservative management until development of local 
or systemic progression with disease-related complaints. At that point patients are treated 
palliatively with TURP or other procedures for urinary tract obstruction and hormonal therapy 
or radiotherapy for palliation of metastatic lesions [51].  
Table 4: Definitions of active surveillance and watchful waiting [52–54]. 
 Active surveillance Watchful waiting 
Treatment intent Curative Palliative 
Follow-up Predefined schedule Patient-specific 
Assessment/markers used 
DRE, PSA, re-biopsy, optional 
MRI 
Not predefined 
Life expectancy > 10 years < 10 years 
Aim 
Minimise treatment-related 
toxicity without compromising 
survival 
Minimise treatment-related 
toxicity 
Comments 
Only for a subgroup of low-risk 
patients 
Can apply to patients with all 
stages 
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1.6.2 Radical prostatectomy 
radical prostatectomy (RP) is the surgical treatment of PCa, which has been performed for 
more than 100 years [55]. This includes the removal of the entire prostate gland and excision 
of both seminal vesicles, along with sufficient surrounding tissue to achieve a negative 
margin. Often, this procedure is accompanied by bilateral PLND [17]. It is considered a gold 
standard treatment of PCa owing to the realization that hormone therapy and chemotherapy 
are never curative and that not all cancer cells can be eradicated consistently by radiation or 
other physical forms of energy, even if the tumor is confined in the prostate gland [56,57]. 
The optimal outcome after RP for clinically localized PCa is freedom from BCR along with 
the recovery of continence and erectile function, a so-called trifecta [58]. Recently 
perioperative complications and positive surgical margins have been added to assess the 
success of the RALP, which called pentafecta [59]. 
1.6.2.1 Open radical prostatectomy 
Perineal RP was initially performed in 1869 by Buchler and popularized in the United States 
by Young in 1905 [55]. In 1947, Millin was the first to describe the retro-pubic approach to 
RP and the morbidity of RP was reduced substantially after several detailed anatomic studies 
performed in fetal and adult cadavers in the late 1970s and early 1980s provided critical 
insight into the periprostatic anatomy, especially that of the dorsal vein complex, the 
neurovascular bundle and the striated urethral sphincter [60–62].  
1.6.2.2 Laparoscopic radical prostatectomy 
Schuessler and colleagues (1997) performed the first successful laparoscopic radical 
prostatectomy (LRP). At that time, several European teams added to the overall experience 
with this technique, with slowly rose in popularity and soon became a widespread minimally 
invasive alternative to RP, to the extent that many centers considered it as the approach of 
choice for the treatment of the localized PCa due to its advantages, such as the lower blood 
loss and transfusion rate associated with the laparoscopic approach, together with shorter 
hospital stay, reduced catheterization time, better pain control and the faster return to 
everyday activities [63].  
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1.6.2.3 Robotic assisted laparoscopic radical prostatectomy (RALP) 
The first case was reported in 2000, thus ushering in a new era of minimally invasive surgery 
[64]. Da Vinci robot offered numerous advantages as it was capable of overcoming several of 
the obstacles present in laparoscopic surgery by providing improved visualization, increased 
dexterity, restored proper hand-eye coordination and an ergonomic position for the surgeon. 
Additionally, the system offers a 3D-image with a 12-foldmagnification (contingent upon the 
distance from the tissue), thus providing views that allow meticulous dissection to be 
performed. Since the camera is controlled by the surgeon, he or she can always maintain a 
stable, optimal view of the surgical field without concern for exhaustion of the camera-driver 
as in conventional laparoscopy [65]. Despite these well-recognized benefits, the current 
robotic platforms are not without profound drawbacks. Most outstandingly, the cost of 
acquiring and maintaining this new technology can be prohibitive [66]. Despite this, RALP 
has virtually replaced LRP in many centers in the world and the overwhelming majority of 
new surgeons have adopted RALP as their preferred surgical approach for PCa [67]. 
1.6.2.4 Complications of radical prostatectomy 
Mortality and morbidity remain primary methods for assessing advantages and disadvantages 
of different surgical techniques and approaches. The incidence of postoperative complications 
is most frequently used as marker of surgical quality [68]. Therefore, measurement of 
morbidity requires an accurate definition of a surgical complication, which is defined as ‘‘an 
undesirable, unintended and direct result of an operation affecting the patient which would 
not have occurred had the operation gone as well as could reasonably be hoped.’’ [69,70]. 
In 2004, Dindo et al. presented a classification of surgical complications utilizing five grades 
containing seven levels (Table 5) [71]. This adjustment was implemented to add more 
precision and depend on whether an intervention due to the complication preformed under 
general anesthesia or not, admission to intensive care unit or not, occurrence a single or 
multiple-organ failure, which based on the type of therapy required to treat the complication. 
This modified classification, which is known as the Clavien- Dindo system, has widely been 
used in recent years by urologists [69].  
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Table 5: The Clavien - Dindo classification of surgical complications. 
Grade Definition 
Grade I 
Any deviation from the normal postoperative course without the need for 
pharmacological treatment or surgical, endoscopic and radiological interventions 
Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, 
diuretics, electrolytes and physiotherapy. This grade also includes wound infections 
opened at the bedside 
Grade II 
Requiring pharmacological treatment with drugs other than such allowed for grade I 
complications 
Blood transfusions and total parenteral nutrition are also included 
Grade III Requiring surgical, endoscopic or radiological intervention 
 Grade IIIa Intervention not under general anesthesia 
 Grade IIIb Intervention under general anesthesia 
Grade IV 
Life-threatening complication (including CNS complications)* requiring IC/ICU 
management 
 Grade IVa Single organ dysfunction (including dialysis) 
 Grade IVb Multi-organ dysfunction 
Grade V Death of a patient 
 If the patient suffers from a complication at the time of discharge the suffix “d” (for 
“disability”) is added to the respective grade of complication. This label indicates 
the need for a follow-up to fully evaluate the complication. 
Suffix “d” 
 
 
*Brain hemorrhage, ischemic stroke, subarrachnoidal bleeding, but excluding transient ischemic attacks. CNS, central 
nervous system; IC, intermediate care; ICU, intensive care unit. 
 
RP is considered one of the major surgical interventions in the field of urology and similar to 
other major surgeries, complications may occur; these can be intraoperative complications e.g 
hemorrhage usually arising from venous structures, as well as vascular, intestinal, rectal, 
bladder, and/or ureteral injuries. Early postoperative complications include: hemorrhage, 
urinary leak or fistula, thrombo-embolic and cardiovascular events, urinary tract infection, 
lymphocele and wound problems and late complications may consist in erectile dysfunction, 
urinary incontinence, inguinal hernia and urethral stricture [56]. 
Surgical site infections (SSIs) are the most common health associated infections and present a 
problem in all surgical fields accounting for 2-5% of surgical complications in the United 
States [72]. This remains a major limiting factor for advancing the horizons of surgery despite 
the progress made in surgical control and SSIs continue to present a major cause of morbidity 
and extended hospital stay as well as aneconomic burden to the health care systems [73].  
SSI is defined as an infection at or near the site of the surgical incision within 30 days of an 
operative procedure or where implants have been placed; this time period can be extended to 
1 year if the infection appears to be related to the procedure [74].  
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Four classes of surgical wounds have been described: clean, clean-contaminated, 
contaminated and dirty (Table 6) [75]. The simplicity of this classification system has resulted 
in widespread use to predict the rate of infection after surgery.  
Table 6: Classification of surgical wounds according to the extent of microbial contamination. 
Classification Criteria 
Clean 
Elective, nonemergency, non-traumatic case, primarily closed; no acute inflammation; 
no break in aseptic technique; respiratory, gastrointestinal, biliary and genitourinary 
tracts not entered. 
Clean-contaminated 
Urgent or emergency case that is otherwise clean; elective opening of respiratory, 
gastrointestinal, biliary, or genitourinary tract with minimal spillage (e.g., 
appendectomy) not encountering infected urine or bile; minor aseptic technique break. 
Contaminated 
Non-purulent inflammation; gross spillage from gastrointestinal tract; entry into biliary 
or genitourinary tract in the presence of infected bile or urine; major break in aseptic 
technique; penetrating trauma <4 hours old; chronic open wounds to be grafted or 
covered. 
Dirty 
Purulent inflammation (e.g., abscess); preoperative perforation of respiratory, 
gastrointestinal, biliary, or genitourinary tract; penetrating trauma >4 hours old. 
 
There are 3 different sorts of SSIs defined by the Centers for Disease Control and Prevention 
(CDC) [76]. According to these criteria, SSIs are classified as either incisional or organ/space; 
incisional SSIs are further sub-classified as superficial (involving only skin and subcutaneous 
tissue) and deep (involving underlying soft tissue). Table 7 further elaborates the CDC 
classification system, which has been widely adopted by surveillance and surgical staff. In 
Germany, there is an OP-KISS protocol to define and standardize data collection of the SSIs 
and analysis in order to obtain reference data for internal quality assurance and to find the 
relation between the number of actual SSIs and the number of infections expected, depend on 
the patient’s risk factor [77]. 
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Table 7: Surgical Site Infections (SSIs) as classified by the Centers for Disease Control and Prevention.  
Superficial Incisional SSIs 
Infection occurs after the operation and infection involves only skin or subcutaneous tissue of the incision. 
Deep Incisional SSIs 
Infection occurs after the operation if no implant* is left in place or within 1 year if implant is in place and the 
infection appears to be related to the operation and infection involves deep soft tissues (e. g, fascial and muscle 
layers) of the incision.  
Organ/Space SSIs 
Infection occurs after the operation if no implant is left in place or within 1 year if implant is in place and the 
infection appears to be related to the operation and infection involves any part of the anatomy (e. g., organs or 
spaces), other than the incision, which was opened or manipulated during an operation.  
Numerous risk factors influence the wound infection rate and thus the risk of developing SSIs 
in the postoperative period. These factors can be either patient-related (coincident remote site 
infections or colonisation, diabetes, cigarette smoking, systemic steroid use, obesity >20% 
ideal body weight and poor nutritional status), or surgery-related (emergency procedures, long 
procedure length, the use of non-absorbable sutures, foreign bodies, copious use of 
subcutaneous electrocautery, excessive blood loss and hypothermia) [74,76,78]. 
1.7 Issue and hypothesis 
There are only few studies comparing the perioperative complication rates of RALP with 
those of the open surgical approach. Our department’s policy is to assess the perioperative 
outcome by recording and categorizing the complications of RP according to the Clavien-
Dindo classification. In doing so, we are trying to answer many questions, e. g. how we can 
optimize our surgical treatment of PCa and how we can avoid complications, which type of 
RP approach has the better perioperative outcome and the lower complications rate. 
Moreover, we assessed the applicability of the Clavien- Dindo classification for RP 
complications in our department. Therefore, we designed a retrospective study to evaluate the 
patients who underwent RP in the period of January 2011 to March 2015 at the Department of 
Urology and Pediatric Urology of the University Hospital Schleswig-Holstein, Campus Kiel, 
to find answers to the above issues. 
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2. Objectives: 
2.1 To make a statistic analysis comparing the preoperative and operative parameters of 
RRP and RALP.   
2.2 To determine and compare the incidence of postoperative complications within 3 months 
after RRP and RALP.   
2.3 To determine whether the surgical approach influences the incidence of postoperative 
complications. 
2.4 To evaluate the result of RALP as performed by surgeons not previously trained in 
conventional laparoscopy or radical prostatectomy and to analyze the learning curve. 
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3. Patients and Methods: 
The data shown in this study reflect patients who were treated with RP, either RRP or RALP 
for a confirmed diagnosis of PCa, regardless of whether it was performed as a primary 
curative treatment or a salvage operation. A retrospective case series study was conducted to 
report and compare the perioperative outcome and complications after RP at the Department 
of Urology and Pediatric Urology of the University Hospital Schleswig-Holstein, Campus 
Kiel, in the period between January 2011 and March 2015. 
3.1 The standard patient protocol in both groups (RRP and RALP): 
i) Preoperative:  
 The patients were admitted to our department the day before the operation to assess their 
fitness to undergo surgery and for laboratory investigation (complete blood picture and 
urine analysis).  
 The co–morbidities are documented according to the ASA classification (American 
Society of Anesthesiologists) 
ii) Operative:  
 All operations were performed under general anesthesia. The operative data are recorded 
as follows: type of surgery, with or without extended LN dissection, with or without 
nerve-sparing procedures, duration of surgical intervention and surgical complication if 
applicable. 
iii) Postoperative: 
 Complete blood picture and abdominal ultrasound were performed between 6 and 24 
hours postoperatively. 
 The two intraoperative drains, easy flow in RRP and Robinson 21 French drain in RALP, 
were usually removed between the 3rd and the 5th postoperative day.  
  Preoperative single-shot antibiotic and postoperative antithrombotic prophylaxis were 
administered. 
 A cystogram was performed in both groups on the 7th postoperative day to assess the 
integrity of vesico-urethral anastomosis; the urethral catheter was removed if no leakage 
appeared in the cystogram.  
 The patient was usually discharged from our department on the 8th postoperative day. 
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3.2 A descriptive statistical comparative analysis was performed regarding the following 
parameters:  
i) Preoperative data: 
 Age of the patient  
 BMI 
 ASA score 
 Hemoglobin (HB) g/dl, Hematocrit (HC) in % and White blood cells (WBCs) x106/μl on 
the day before the operation. 
 Preoperative PSA and prostatic volume. 
ii) Operative data: 
 Operative type (RRP or RALP) 
 Pelvic Lymph Node Dissection (PLND) Yes/No 
 Nerve-sparing surgery: Yes/No 
 Operative time in minutes (min). 
 Complications;  
1- Open conversion for RALP 
2- Vascular injuries: any intraoperative vascular injury, whatever its sequelae 
3- Rectal, bladder and ureteral injury 
iii) Postoperative data: 
 Hemoglobin (HB) g/dl, Hematocrit (HC) in % and White blood cells (WBCs) x106/μl 
were determined between 6 and 24 hours postoperatively. 
 Oncological data: 
1- Pathological tumor stage (pT- stage). 
2- Pathological LN stage and number of LN removed. 
3- Gleason score  
4- Surgical margin (we considered the surgical margin as an indicator of the 
oncological outcome)  
 Complications within 90 days after the operation: 
1- Hemorrhagic complications in the form of hemoperitoneum and/or pelvic 
hematoma 
2- Anastomotic insufficiency, which is considered to present if leakage is shown 
in the first postoperative cystogram 
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3- Urethral stricture or urinary retention, occuring within 3 months postoperativly 
and requiring intervention. 
4- Lymphoceles, which treated conservatively or requiring intervention, either 
under local anathesia e. g radiologically guided drain insertion or under general 
ananthesia e. g laparoscopic peritoneal fenestration. 
5- Postoperative ileus, requiring medical treatment or other form of intervention 
6- Transfusion of blood or fresh frozen plasma (FFP) 
7- Thrombo-embolic complications, diagnosed by radiological investigation, e. g. 
CT chest for pulmonary embolism or Doppler ultrasound for deep venous 
thrombosis (DVT). 
8- Urinary tract infections, i.e any microbiologically proven bacterial infection of 
urine. 
9- SSIs; such as wound erythema or cellulitis necessitating antibiotic therapy 
and/or surgical intervention.  
 All hospitalization periods were calculated by including the preoperative day. 
 Catheterization time was calculated in days from the operation day until the day of 
catheter removal. 
3.3 Statistical analysis: 
We performed a descriptive statistical analysis of pooled data by using:  
 Mann-Whitney U Test was used to compare between medians; the independent t-test 
was used to compare the mean across the groups and the Chi-squared test and Fisher’s 
exact test were used for categorical variables. 
 Correlations between different items in our study were done using Spearman or 
Pearson correlation coefficient. 
 Statistical significance was set at (p<0.05). All reported p values are two-sided. 
 Statistical analyses were performed with the Statistical Package for Social Science 
(SPSS), version 21.0. 
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4. Results:  
Throughout the period from January 2011 to March 2015, 285 patients underwent RP, either 
RRP or RALP, at our department; 187 (66%) of these patients underwent RRP and 98 (34%) 
underwent RALP (Fig. 2). 
In January 2013, the first case of RALP was performed at our department; from this time the 
majority of the patients underwent RALP and as the numbers in RALP were increasing, the 
number of patients who underwent RRP decreased gradually down to just five cases in 2014; 
in 2015 all cases were done with RALP (Table 8).  
The age distribution of men who underwent RALP shows that about 50% were aged 70-79 
years; none of the patients was under 50 years or over 80 years old. In contrast, of the men 
who underwent RRP only 45% were aged 70-79 years , only 2% of the patients were aged 40 
– 49 years and 1% was over 80 years old (Table 9 and Fig.3).  
The cohort data in Table 10 show that the average age of men who underwent RP was 68.1 
years, the average body mass index (BMI) was 27.2 kg/m
2
, 68% of the patients were 
overweight or obese (Fig. 4), 72.4% of the men had ASA score II, the median of the 
preoperative prostatic specific antigen (PSA) was 8.1 ng/mL, more than the half (54.2%) of 
the patients had a PSA in between 4 and 10 ng/mL (Fig. 5), and an average preoperative 
prostatic volume of 42.9 cm
3
.  
The patients who underwent RALP were more likely to have nerve-sparing procedures 
(82.7% vs. 47.1%, p ˂ .0001) (Fig.5) and had a longer operative time with (mean 331.3 min. 
vs. 269.5 min, p ˂ .0001) (Fig.6). However, RALP caused less perioperative HC loss (mean 
10.6% vs. 12.6%, p = .033) (Fig.8), lower catheterization times (mean 9.2 days vs. 12.6 days, 
p ˂ .0001) and shorter mean hospitalization time (9.7 days vs. 13.5 days, p ˂ .0001) (Fig.8). 
Almost all patients underwent LN dissections in both groups (Table 11).  
The oncological data that are presented in Table 12 reveal a statistically significant difference 
between groups regarding pT sage, N stage and safety margins. More than 50% of the patients 
who underwent RP had a pathological tumor stage (pT2), only 0.4% had pT4 (Fig. 10) and 
more than 75% of the patients had LN metastases-free status (N0) (Fig. 11); more than 65% 
of the safety margins were negative (Fig. 12) and about 30% of the Gleason scores of 
removed PCa were 3+4= 7a. 
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Table 13 summarizes the percentage of the incidence of postoperative complications for each 
group. In total, 285 patients underwent RP over the period of the last 4 years and we observed 
complications in 154 patients (54%) (Fig.12). A statistically significant differences between 
the groups were found regarding the total incidence of the postoperative complications 
(RALP 38.8% vs. RRP 62%, p = .001) (Fig.13), anastomotic insufficiency (RALP 10.2% vs. 
RRP 20%, p =. 024) and hemorrhagic complications (RALP 4% vs. RRP 0.5%, p =.033) 
(Fig.14). 
The presented data in Table 14 classify the complications according to the Clavien-Dindo 
Classification and show that about one third (34%) of the patients had minor complications 
(Clavien-Dindo Classification I and II) and about 16% of the patients had major 
complications (> Grade II, Fig. 16). 
Thus, we observe from this statistical analysis that; 
 The patients underwent RALP were more likely to have nerve-sparing procedures, on 
the other hand longer operative timewas longer. 
 The patients who underwent RALP had a shorter catheterization and hospitalization 
time.  
 The patients who underwent RALP had negative surgical margins more often. 
 The patients who underwent RALP had lower complications rates in all modified 
Clavien-Dindo classes than those who underwent RRP. 
 The patients who underwent RALP had a lower incidence of anastomotic insufficiency 
and SSIs than those who underwent RRP. 
 The patients who underwent RALP were more prone to haemorrhagic complications 
than those who underwent RRP. 
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4.1 Tables: 
Table 8: Number of surgeries performed in each calendar year. 
Years RALP RRP Total 
2011 - 81  81  
2012 - 67  69  
2013 30  32 62  
2014 55  5  60  
March, 2015 13  - 13  
Total 98  187  285  
  
Table 9: Age distribution. 
Age: (years) RALP RRP Total 
40- 49 - 3 3 
50-59 8 20 28 
60-69 41 78 119 
70-79 49 84 113 
>80 - 2 2 
Mean ± SD 68.9 ± 6 67.7 ± 6.9 68.1 ± 6.7  
 
Table 10: Preoperative data. 
 RALP RRP Total P value 
Total no. of cases 98 187 285  
Age at operation, yr.     
Mean
 a
± SD 68.9 ± 6 67.7 ± 6.9 68.1 ± 6.7 .196 
Medianb (Range) 69.5 (51-79) 68 (47-85) 69 (47-85) .203 
BMI, kg/m
2
, 
     
Mean
 a
± SD 26.8 ± 2.9 27.3 ± 4 27.2 ± 3.8 .035 
Medianb (Range) 26.3 (22.1-34) 26.4 (19.5-42.4) 26.4 (19.5-42.4) .672 
BMI
c 
, %    .154 
Normal (18.5–24.9) 26.8 33.3 32  
Overweight (25–29.9) 61 44.8 48.1  
Obese (30 or greater) 12.2 21.8 19.9  
ASA
c 
,%    .517 
I 1.9 5.3 4.4  
II 72.2 72.5 72.4  
III 25.9 22.2 23.1  
Preoperative PSA ng/mL, median 
b 
7.4 8.7 8.1 .082 
PSA
c
 ng/mL, %    .003
*
 
˂4 4.1 9.7 7.7 
 
4 to ˂ 10 68.4 46.8 54.2  
10 – 20 19.4 23.7 22.2  
>20 8.2 19.9 15.8  
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Preoperative HB
 
(g/dl)
 
    .004
*
 
Mean
 a
 ± SD 14.4 ± 1.4 14.6 ± 1 14.5 ± 1.2 
 
Median
b
 (Range) 14.5 (10.1-17.2) 14.6 (10.6- 17.3) 14.6 (10.1- 17.3) ˂ .0001* 
Preoperative HC
 
%
 
     
Mean
 a
± SD 41.7 ± 3.9 41.9 ± 3.9 41.8 ± 3.7 .104 
Medianb (Range) 42 (26- 49) 42 (15- 49) 42 (15- 49) ˂ .0001
*
 
WBCs
 (x106/μl)    .1 
Mean
 a
± SD 6.7 ± 2.9  6.7 ± 1.6 6.7 ± 2.2  
Medianb (Range) 6.2 (1.8- 29.7) 6.5 (3.4- 12.1) 6.4 (1.7-29.7) ˂ .0001
*
 
Prostatic volume, cm
3
      
Mean
 a
± SD 45.4 ± 23.1 41.6 ± 20.1 42.9 ± 21.2 .279 
Medianb (Range) 40 (13-149) 37 (12-160) 38 (12-160) .236 
a 
Independent T- test                                                                                                                      * Statistical significant difference (P < 0.05) 
b 
Mann-Whitney U Test 
c
 Chi-squared test 
 
 
Table 11: Perioperative data.  
 
 RALP RRP Total P value 
Cases no. 98 187 285  
Nerve sparing 
c
, %    ˂ .0001
*
 
Yes 82.7 47.1 59.3  
Lymph node dissection 
c
, %    .468 
Yes 100 99.5 99.6  
Operative time, min      
Mean
 a
 ± SD 331.3 ± 57.1 269.5± 47.9 290.7 ± 58.7 ˂ .0001* 
Median b (Range) 321 (210- 503) 270 (150-450) 285 (150-503) ˂ .0001* 
Catheterization time, days     
Mean
 a
 ± SD 9.2 ± 5.6 12.6 ± 10.2 11.4 ± 9 .001
* 
Median c (Range) 7 (6-36) 8 (6-69) 7 (6-69) ˂ .0001* 
Hospitalization time, days     
Mean
 a
 ± SD 9.7 ± 3.4 13.5 ± 9.1 12.2 ± 7.9 ˂ .0001
*
 
Median b (Range) 9 (7-35) 10 (8-71) 9 (7-71) ˂ .0001* 
HB loss g/dl     
Mean
 a
 ± SD 3.9 ± 1.8 4.4 ± 1.3 4.2 ± 1.5 .06 
Median 
b
 (Range) 3.6 (0.3-13.4) 4.4 (0.6-8) 4.1 (0.3-13.4) ˂ .0001
*
 
HC loss %     
Mean
 a
 ± SD 10.6 ± 4.7 12.6 ± 3.9 11.9 ± 4.3 .033
* 
Median 
b
 (Range) 10 (1-23) 13 (2- 24) 12 (1-24) ˂ .0001
*
 
WBCs difference (x106/μl)     
Mean
 a
 ± SD 2.1 ± 2.7 2.8 ± 2.8 3.4 ± 2.9 .078 
Median 
b
 (Range) 1.9 (-12.2 – 11.5) 2.8 (-2.3 – 19.8) 3.4 (-12.2 – 19.8) ˂ .0001
* 
a 
Independent T- test                                                                                                            * Statistical significant difference (P < 0.05) 
b 
Mann-Whitney U Test
 
c
 Chi-squared test 
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Table 12: Oncological outcome. 
 
 RALP RRP Total P value 
pT stage 
c
, %    .022
* 
T2 68.4 54.3 59.2  
T3 30.6 45.7 40.5  
T4 1 0 0.4  
N stage
c
, %    .001
* 
Nx 3.1 1.1 1.8  
N0 86.7 70.1 75.8  
N1 10.2 28.9 22.5  
Gleason score 
c
, %    .079 
< 6 1 1.1 1.1  
6 23.5 21.6 22.3  
3+4 32.7 27.6 29.3  
4+3 28.6 20.5 23.3  
≥ 8 14.3 29.2 24  
No. Of lymph node removed      
Mean 
a
± SE 15.6 ± 8.8 26.2 ± 10.6 22.6± 11.2 .113 
Median b (Range) 15 (0-40) 25 (3-65) 22 (0-65) ˂ .0001
*
 
Margins 
c
, %    ˂ .0001
*
 
Positive multiple  12.2 4.3 7  
Positive one  9.2 32.3 24.3  
Negative  78.6 63.4 68.7  
a 
Independent T- test                                                                                                                          * Statistical significant difference (P < 0.05) 
b 
Mann-Whitney U Test 
 
c
 Chi-squared test 
 
Table 13: Number and percentage of the incidence of postoperative complication. 
 RALP RRP Total  P value r value 
Total of complicated cases: No. (%) 38 (38.8) 116 (62) 154 (54) .001
* 
.058 
Vascular injuries: No. (%) 3 (3.1) 0 3 (1.1) .041
*
 .041 
Rectal injury: No. (%) 1 (1) 3 (1.6) 4 (1.4) .569 .045 
Anastomotic insufficiency: No. (%) 10 (10.2) 37 (19.8) 47 (16.6) .024
* 
.242 
Hemorrhagic complications: No. (%) 4 (4) 1 (0.5) 5 (1.8) .05
* 
.240 
Postoperative urinary difficulty: No. (%) 1 (1) 1 (0.5) 2 (0.7) .573 .032 
Lymphocele: No. (%) 8 (8.1) 26 (13.9) 34 (11.9) .102 .055 
Thromboembolic complication: No. (%) 1 (1) 4 (2.0) 5 (1.8) .434 .051 
Urinary tract infections: No. (%) 2 (2) 5 (2.7) 7 (2.5) .540 .057 
SSIs: No. (%) 2 (2) 17 (9.1) 19 (6.7) .001
* 
.179 
Ileus: No. (%) 2 (2) 4 (2.0) 6 (2.1) .656 .059 
Transfusion: No. (%) 6 (6.1) 14 (7.6) 20 (7.1) .426 .057 
Uretric injury or stricture: No. (%) 0 2 (1.2) 2 (0.7) .427 .022 
Open Conversion: No. (%) 1 (1) 0 1 (0.4) .465 .043 
Death: No. (%) 0 2 (1.2) 0.7 .43 .022 
Fisher’s exact test                                                                                                                        * Statistical significant difference (P < 0.05) 
 
 
 Results  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
05 
 
Table 14: Numbers of the complicated cases according to modified Clavien-Dindo 
classification. 
 
Grade Definition RALP RRP No. 
% to 
total no. 
Grade I 
 
 Leakage occurred in 35 cases after RRP and in 10 cases 
after RALP and was treated with prolonged 
catheterization. 
 One patient developed a subcutaneous hematoma due 
to RALP.  
 8 RRP cases and 2 RALP cases developed small 
lymphoceles. 
 4 RRP cases and 2 RALP cases developed postoperative 
ileus. 
 3 RRP cases developed postoperative superficial SSIs. 
 Open conversion occurred in one case during RALP 
16 50 66 23.1 
Grade II  2 RRP cases of incomplete rectal injury discovered 
intraoperatively were treated with primary closure and 
postoperatively with total parenteral nutrition. 
 2 RALP cases and 5 RRP cases were diagnosed with a 
positive urinary culture of >105 colonies/mL urine and 
treated by intravenous antibiotics. 
 14 RRP cases and 6 RALP cases needed postoperative 
transfusion either erythrocyte concentrate, FFP and/ or 
platelet concentrate. 
 2 RRP cases developed postoperative DVT, which were 
treated by anticoagulant therapy. 
8 23 31 10.8 
Grade IIIa  Leakage, in one case of RRP was treated by bilateral 
PCN under local anesthesia. 
 3 cases RRP and 3cases RALP presented with 
postoperative lymphoceles that were treated by US-/ 
CT-guided pig tail insertion under local anesthesia. 
 2 RALP cases presented with infected lymphoceles 
(space SSIs) that were treated by CT- guided pig tail 
insertion. 
5 4 9 3.1 
Grade IIIb  In one RALP and one case RRP case, rectal injury was 
discovered intraoperatively and treated with primary 
closure and a safety proximal ileostomy that required 
closure after 6-8 weeks.  
 In one case of RRP anastemotic insufficiency was 
detected requiring urethrocystoscopy to evaluate the 
anastomotic area under general anesthesia. 
  In 3 RALP cases and one RRP case postoperative 
bleeding and pelvic or retroperitoneal hematoma 
occurred requiring immediate surgical evacuation 
under general anesthesia and/or bilateral immobilization 
of the internal iliac arteries. 
 In one case of RALP and RRP each, difficulty of 
micturition developed within 3 months postoperatively; 
this was was treated by transurethral resection of the 
anastomotic area. 
 15 RRP cases and 3 RALP cases presented with 
postoperative lymphoceles that were treated by 
laparoscopic peritoneal fenestration. 
 13 RRP cases developed postoperative SSIs and wound 
dehiscence (Deep incisional SSIs), which were treated 
8 35 43 15.1 
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by regular exchange of the Vacuum-Assisted Closure 
system (VAC). 
 One cases RRP presented by infected lymphocele (space 
SSIs) that treated by open surgical evacuation and 
lavage. 
 One case RRP developed postoperative ureteric 
stricture that need re-exploration and re-implantation of 
the ureter into the bladder under general anesthesia. 
 One case RRP was intraoperative ureteric injuries due 
to marked retroperitoneal fibrosis, which treated by 
primary closure and JJ stint was inserted and one month 
after the operation removed. 
Grade IVa  One case RRP developed postoperative massive 
pulmonary embolism and was admitted in ICU. 
 One case RRP and one case RALP developed 
postoperative cerebral stroke which treated 
anticoagulant therapy with development of neurological 
affections. 
1 2 2 0.7 
Grade IVb  0 0 0 0 0 
Grade V  Two cases.  0 2 2 0.7 
  38 116 154  
 
 
 
 
 
 Results  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
03 
 
4.2 Figures: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Percentage of RRP and RARP, % 
Figure 3: Age distribution in both groups 
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Figure 4: Percentage of BMI according to the surgical technique, % 
Figure 5: Percentage of preoperative PSA mg/dl, % 
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Figure 6: Percentage of nerve sparing according to surgical technique, % 
 
Figure 7: Mean operative time, min 
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Figure 9: Mean catheterization time and hospital stay, days 
Figure 8: Mean operative HC loss, % 
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Figure 10: Percentage of pathological T stage, % 
Figure 11: Percentage of N stage, % 
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Figure 12: Percentage of surgical Margins, % 
Figure 13: Total Incidence of complications, % 
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Figure 15: Incidence of complications in relation to surgical technique, % 
Figure 14: Incidence of complications according to surgical technique, % 
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Figure 16: Percentage of complicated cases in relation to operation type and modified 
Clavien-Dindo Classification, % 
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5. Discussion:  
For valid results, the ideal methodological setting for comparing RRP with RALP should be 
based on consistent surgical procedures performed at a single institution with a clearly 
defined surgical technique, grading complications and consistent pathological assessment 
[79]. For each surgical procedure, perioperative  complications are the major indicators of 
surgical results, particularly in RP where different surgical approaches are available [80].  
In this study we compared the short-term perioperative outcome (within 90 days 
postoperatively), with respect to the oncological and functional results and the complications 
rates of RALP versus RRP in a single institution. In doing so, we are also reporting and 
evaluating the experience of our center changing from the open approach to a robot-assisted 
approach. The open approach had been performed in a large volume of cases by two highly 
experienced surgeons without any laparoscopic experience; both started RALP at same time 
so that our data include a learning curve; our aim was to confirm that RALP could be 
accomplished by surgeons who had not previously been trained in conventional LRP and to 
determine whether this change of the surgical approach would influence the incidence of 
complications after RP. 
This descriptive and retrospective study has some obvious limitations. Firstly, it is difficult to 
record all complications objectively as some colleagues only report major complications of 
vital importance and disregard minor complications. Secondly, the distinction between the 
different Clavien classification grades is sometimes unclear and the allocation to different 
complication grades underlies a certain degree of subjectiveness.  
5.1 Preoperative  data 
5.1.1 Age 
Between 1962 and 2002 the average life expectancy in the German population increased from 
67.1 to 75.6 years in men and from 72.7 to 81.3 years in women with an average gain of 
approximately 2.2 years per decade in both genders [81]. Traditionally, RP used to be 
restricted to men with a life expectancy of 10 years or more and to cases with a localized PCa 
[17]. The median age of men that underwent RP in our study was 69 years at the time of 
surgery; these men generally had a life expectancy at least 10 years (Table 9 and Fig.3). 
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5.1.2 BMI 
There is a solid relationship between obesity, diabetes, coronary artery disease, hypertension 
and additionally there is a significant impact on mortality in cancer patients, so it is a standout 
amongst the most pressing problems that the healthcare system is facing; an elevated BMI 
also plays a significant role in cancer progress, aggressiveness and even cancer-related 
mortality, especially in PCa, despite the fact that most studies cannot prove this correlation 
[82]. In our study, approximately 68% of the men had an elevated BMI (overweight and 
obesity) (Table 10 and Fig.4). There were a significant differences regarding catheterization 
time and hospitalization time in correlation with different BMI groups, which is generally in 
accordance with the data from randomized controlled trials evaluating the impact of BMI on 
perioperative outcomes (Table 15). 
Table 15: The impact of patients’ BMI on the perioperative outcomes. 
First author Institution Cases 
Operative time, min, 
median/mean 
Catheterization 
duration, d 
In-hospital 
stay, d 
Wiltz, 
2009
a
[83] 
University of Chicago, 
IL, USA 
BMI < 25: 216 
BMI 25–30: 464 
BMI >30: 265 
217 ± 58* 
214 ± 65* 
234 ± 77* 
6 ± 1.1 
6 ± 1.3 
6 ± 1.8 
1.2 ± 0.6 
1.2 ± 1.2 
1.2 ± 1.5 
Moskovic, 
2010
a
[84] 
Mount Sinai Medical 
Center, 
New York, NY, USA 
BMI < 25: 270 
BMI 25–30: 600 
BMI >30: 242 
121* 
122* 
126* 
- 
- 
- 
1.25* 
1.25* 
1.17* 
Zilberman, 
2011
a
[85]. 
Duke University 
Medical 
Center, Durham, NC, 
USA 
BMI < 25: 100 
BMI 25–30: 286 
BMI 30- 34.9: 135 
BMI >35: 34 
159(137-202)* 
181 (151-220)* 
178 (148-230)* 
191 (162-225)* 
- 
- 
- 
- 
- 
- 
- 
- 
Our study 
b 
 Department of Urology 
and Pediatric Urology, 
University Hospital, 
Kiel, Germany. 
BMI < 25: 66 
BMI 25–30: 99 
BMI >30: 41 
283 ± 62 
286 ± 58 
281 ± 52 
11 ±8* 
11 ± 7* 
17 ± 14* 
12 ±.6* 
12 ±7* 
16 ± 14* 
a 
These studies evaluate the impact of BMI on the perioperative  outcome after RALP.                                   
*
 Statistically significant                                                                                                                                     
b
 One way ANOVA 
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5.1.3 Prostatic volume 
Many studies demonstrate that an increased prostate volume is associated with a longer 
operative time, catheterization and hospitalization times and a higher rate of complications 
but not with higher rate of positive surgical margins (PSMs) in RRP or LRP [86,87]. In a 
large RALP series, Link et al 2008 evaluated the impact of the prostate size in a series of 
1847 cases, demonstrating greater blood loss, longer hospital stay and more complications (e. 
g., urinary leak) for larger-sized prostates [88]. Our results are comparable to these data 
(Table 16). 
Table 16: The impact of prostatic volume on the perioperative outcomes. 
First author Institution Cases 
Operative time, 
min, 
median/mean 
Catheterization 
duration, d 
In-hospital 
stay, d 
Link, 
2008a [88] 
City of Hope, Duarte, 
CA, USA  
Prostate volume <30 cm3: 69  
Prostate volume 30–49 cm3: 883  
Prostate volume 50–69 cm3: 568  
Prostate volume >70 cm3: 327 
168 ± 42* 
168 ±42* 
180 ± 48* 
192 ± 48* 
6 (6–8)* 
6 (6–8)* 
6 (6–8)* 
7 (7–8)* 
- 
- 
- 
- 
Allaparthi, 
2010a [89] 
Turfts University, 
Brighton, 
MS, USA 
Prostate volume <30 cm3: 10  
Prostate volume 30–49 cm3: 182 
Prostate volume 50–79 cm3: 91  
Prostate volume >80 cm3: 12 
129 ± 28 
127 ±20 
128 ± 3 
127 ± 20 
2± 2.7 
1 ± 0.7 
- 
- 
1 
1.2 (1-12) 
1(1-2) 
1.4(1-5) 
Martinez, 
2010a [90] 
University of Western 
Ontario, 
London, Ontario, 
Canada 
Prostate volume <40 cm3: 75  
Prostate volume 40–60 cm3: 51 
Prostate volume >60 cm3: 24 
205± 43* 
201 ±47* 
232 ±48* 
- 
- 
- 
3.3 ± 2.2 
3.2 ± 2.2 
3.1 ± 1.5 
Skolarus, 
2010a [91] 
University of 
Michigan 
Health System, Ann 
Arbor, MI, USA 
Prostate volume <50 cm3: 582 
Prostate volume 50–100 cm3: 279 
Prostate volume >100 cm3: 24 
232* 
248* 
250* 
- 
- 
- 
- 
- 
- 
Huang, 
2011a [92] 
Harvard Medical 
School, 
Boston, MA, USA 
Prostate size 24-41 g: 221 
Prostate size 42-50 g: 221 
Prostate size 51-62 g: 221 
Prostate size > 62 g: 221 
149.1 ± 39.3* 
153.3 ± 40.5* 
158.0 ± 40.1* 
164.2 ± 48.4* 
7.6 ± 3.2* 
7.7 ± 2.8* 
7.6 ± 2.3* 
8.5 ± 4.3* 
1.2 ± 1* 
1.2 ± 0.7* 
1.1 ± 0.5* 
1.3 ± 1* 
Our study b  Department of 
Urology and Pediatric 
Urology, University 
Hospital, Kiel, 
Germany. 
Prostate volume <30 cm3: 63  
Prostate volume 30–49 cm3: 121  
Prostate volume 50–69 cm3: 55  
Prostate volume >70 cm3: 27 
288 ±53 
287 ± 62 
292 ± 51 
301 ± 68 
10.6 ±6.5* 
10.8 ± 6.5* 
9.4 ± 5.1* 
14.9 ±14.7* 
12.4 ±.8.4 
11.8 ±5.7 
11.5 ± 6.7 
12.6 ± 7.1 
a 
These studies are evaluating the impact of BMI on perioperative  outcome after RALP.                                
*
 Statistically significant 
b
 One way ANOVA   
                                                                                                                                         
5.2 Perioperative data 
5.2.1 Pelvic lymph node dissection (PLND) 
The most effective method for detecting LN metastases in PCa is PLND; this allows for 
appropriate staging, accurate predictions and can help to choose optimal post-surgical follow-
up treatment, i. e. the choice between either adjuvant or salvage therapy [93]. PLND includes 
the removal of the nodes overlying the external iliac artery and vein, the nodes within the 
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obturator fossa that are located cranially and caudally to the obturator nerve and the nodes 
medial and lateral to the internal iliac artery (Table 17) [94,95]. The advantage of PLND for 
improved staging and/or increased cancer curativity should be weighed against intraoperative  
and postoperative complications [93]. We routinely perform PLND in during each RP despite 
its supposed association with increased surgical time and the risk of complications; however, 
our data show no significant correlation between PLND, the incidence of complications and 
operative time (Spearman correlation Coefficient, p = 0.062 and 0.059 respectively). 
Table 17: Recommendation of German Urological Society regarding PLND in localized PCa 
[95]. 
Recommendations / Statements Grade of 
recommendation 
Patients with PCa should be informed about the risk of LN 
metastasis and the advantages and disadvantages of 
lymphadenectomy. 
Total agreement: 98% 
A 
In patients with a low risk PCa (pT1c and PSA <10 and Gleason 
≤ 6) a lymphadenectomy is not indicated. 
Total agreement: 91% 
C 
The more extensive the lymphadenectomy, the greater the 
chance of nodal positive findings. This allows for exact staging 
and early initiation of adjuvant therapy with proven LN 
metastases. 
Total agreement: 96% 
Statement 
If lymphadenectomy performed, at least 10 lymph nodes should 
be removed.  
Total agreement: 76% 
B 
Currently, there is no evidence that extended lymphadenectomy 
causes a survival benefit for nodal-positive or nodal-negative 
patients without adjuvant measures. However, there are 
indications that progression-free survival is influenced 
favorably. 
Total agreement: 87% 
Statement 
A Based on clinical studies of good quality and consistency that addressed the specific recommendations, including at least one randomised trial 
B Based on well-conducted clinical studies, but without randomised clinical trials 
C Made despite the absence of directly applicable clinical studies of good quality 
5.2.2 Nerve-sparing RP 
The development of nerve-sparing anatomic RP by Walsh and colleagues has led to improved 
potency rates, however the results regarding potency preservation published in the literature 
are not satisfactory [96]. A majority of surgeons agrees that the ideal candidate for a nerve-
sparing procedure is a preoperatively fully potent patient with an organ-confined cancer, that 
is, a clinical T1/T2a-b disease [97].  
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Patients who underwent nerve-sparing procedures were more likely to have PSMs, as there is 
a significant yet weak positive correlation between nerve-sparing procedures and positive 
surgical margins (spearman correlations coefficient r = .154, p = .009 “own data”). These 
findings seem to be a logical consequence of nerve-sparing procedures and they are similar to 
other non-randomized trials (Table 18). 
Table 18: The correlations between nerves-sparing RP and positive surgical margin. 
First author Institution  NSRP,% non-NSRP,% P value 
Moore [98], 
2011 
St Vincent ’s Hospital, 
Sydney, NSW, Australia 
PSM 
T2 
T3 
overall 
 
12.3 
40.3 
19.4 
 
21.4 
52.2 
38.6 
 
.871 
.028*a 
Alkhateeb[99], 
2010 
Margaret Hospital, 
University Health Network, 
University of 
Toronto, 
PSM 
T2 
T3 
overall 
 
10.4 
26.3 
13.4 
 
15.7 
24.1 
17.7 
 
0.07 
0.76 
0.11 
Our studya  Department of Urology and 
Pediatric Urology, 
University Hospital, Kiel, 
Germany. 
PSM 
T2 
T3 
overall 
 
13.1 
17.4 
15.1 
 
6.5 
30.4 
16.2 
 
.258 
.284 
.009* 
NSRP - Nerve sparing RP; PSM - Positive surgical margin 
Fisher’s exact test                                                                                                                            * Statistical significant difference (P < 0.05) 
a 
for T3a 
 
5.2.3 Operative time 
The available literature suggests that the duration of RP procedures decreases with surgeon 
experience and skill [100]. The operating time was longer in RALP compared to RRP (331.3 
vs. 269.5 min., p ˂ .0001,”own data”), thus also in all publications due to docking time and 
learning curve. Our data show that procedures involving a large prostate tend to last longer 
(Table 16). However, the operative time seems to be not affected by LN discussion and nerve 
sparing procedures, BMI and pathological T stage, as insignificant correlations between 
operative time and those latter factors.  
5.2.4 Hospitalization time 
Several studies have demonstrated a shorter hospitalization time after RALP as compared 
with RRP (Table 19). A statistically significant difference between both groups was found for 
the length of hospital stay (mean 9.7 vs. 13.5 days, p < 0.001), in favor of RALP (Table 11). 
The variation in hospitalization time at different institutions may reflect differences in 
surgical volume or patient characteristics.  
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A longer hospitalization time was found in patients who had peri-operatve complications, as a 
significant weak-positive correlation was found between hospital stay and rectal injuries 
(Spearman correlation coefficient r = .169, p = 0.004); anastomotic insufficiency (Spearman 
correlation coefficient r = .291, p < 0.001); urinary tract infections (Spearman correlation 
coefficient r = .162, p = 0.006); lymphoceles (Spearman correlation coefficient r = - .145, p = 
0.015); thrombo-embolic complications (Spearman correlation coefficient r = .255, p < 0.001) 
and a significant moderate positive correlation for SSIs (Spearman correlation coefficient r = 
.375, p < 0.001). However, there were insignificant correlations for many other complications, 
e.g hemorrhagic, urinary retention, illus and blood transfusion. 
5.3 Oncologic outcomes  
The pathological examination of the surgical specimen provides crucial information regarding 
prognostic factors that include tumour stage, Gleason score and surgical margin status.  
5.3.1 Positive surgical margins (PSMs) 
PSMs after RP are uniformly considered an adverse outcome associated with failure of the 
surgery to achieve cure of the PCa [101]. Our data shows that patients who underwent RALP 
were more likely to have negative surgical margins; a statistically significant difference 
between both groups was found with respect to PSMs, the outcome in negative surgical 
margins was in favour of RALP (78.8% vs. 63.4%, p < 0.001). 
Table 19 shows the perioperative parameters and the main complications rates in several 
studies comparing RRP and RALP. The outcome of this comparison demonstrates that the 
longer operating time in our study, which may be due to the fact that our operation time 
includes the anesthesia time which is around 30-40 min and in RALP the docking time takes 
about 20-30 min; in addition we have to take into account the learning curve as we only 
started RALP during this time. Moreover, the longer hospitalization time is also accredited to 
the fact that the patient is only discharged after removal of the urethral catheter and owed to 
German health insurance regulations. In his study from Dresden, Germany, Froehner et al, 
2013 shows that the mean hospitalization time in RRP was 7.7 days and in RALP 8 days, 
while in Kiel the duration was 13.5 vs. 9.7 days in RRP and RALP respectively [102].  
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In current data, the complications rates seem to be higher (RRP 62% vs. RALP 38.8%) than 
in the other studies despite excluding the possibility of duplicated numbers as many patients 
had more than one complication; we considered only the worst one according to the modified 
Clavien- Dindo Classification. On the other hand, Wallerstadt et al., 2015 showed the 
complication rates of RRP to be 80.5% vs. RALP 70.1% in a large multi-centers study [103]. 
The outcome after RP, including perioperative , oncologic and Health-Related Quality of Life 
(HRQL), is multi-factorial due to different patient and tumor characteristics as well as the 
surgeons’ experience and surgical technique.  
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Table 19: Perioperative, oncological outcomes and complications rates in the studies compare RRP and RALP.   
First author Institution 
No. of cases, 
type 
Mean 
age, y 
BMI 
Preoperative 
PSA ng/mL, 
median 
Mean 
Prostatic 
vol, cm
3!
 
Median/mean 
operative time, 
min 
HB 
loss 
g/dl 
Hospitalization 
time, days 
Menon[104], 2002 
 Vattikuti Urology Institute, Henry Ford 
Health System, Detroit, Michigan; 
RRP 30 64 30 8,4* 48.4 138* 4.4* 2.3* 
RALP 30 62 30 9.94* 58.8 288* 1.2* 1.5* 
Tewari[105], 2003 
Vattikuti Urology Institute, Henry Ford 
Health System, Detroit, Michigan; 
RRP 100 63.1 27.6 7.3 48.4 163 - 3.5* 
RALP 200 59.9 27.7 6.4 58.8  160 - 1.2* 
Ahlering[106], 
2004 
Department of Urology, University of 
California Irvine, 
Medical Center, Orange, California 
RRP 60 62.7 26.5 8.4 50.7 214 3.3* 2.2* 
RALP 60 62.9 26.3 8.1 52.5 231 1.6* 1.1* 
Nelson[107], 2007 
Department of Urologic Surgery, 
Vanderbilt University Medical Center, 
Nashville, Tennessee 
RRP 374 59.9 - 8.4 - - - 1.23 
RALP 629 59.3 - 6.7 - - - 1.17 
Smith[108], 2007 
Department of Urologic Surgery, 
Vanderbilt University Medical Center, 
Nashville, Tennessee 
RRP 200 61.1 27.8 8.3* 43.9* - - - 
RALP 200 60.3 28.5 6.4* 53* - - - 
Fracalanza[109], 
2008 
Departments of Oncological and Surgical 
Sciences, Urology Clinic, 
RRP 26 68.5* 26.4 6.2 36 127.2* - 8* 
RALP 37 62* 25.5 6.2 40 195.6* - 5* 
Ficarra, [110], 
2008 
Department of Oncological and Surgical 
Sciences, Urology Clinic, University of 
Padua, Padua, Italy 
RRP 105 65* 26 6 40 - - - 
RALP 103 61* 26 6.4 37.5 - - - 
Krambeck[111], 
2009 
Departments of Urology and *Division 
of Biostatistics, Mayo Medical School 
and Mayo Clinic, Rochester, MN, USA 
RRP 588 61 - 5 - - - - 
RALP 294 61 - 4.9 - - - - 
Hohwü[112], 2009  Multi- centers 
RRP 147 56 26.9 11.7 - - - - 
RALP 127 57.9 25.9 7.7 - - - - 
Mirza[113], 2011 
Department of Urology-MS 3016, 
University of Kansas Medical Center, 
3901 Rainbow Boulevard, Kansas City, 
USA 
RRP 180 61.7 - 8.9* - - - 2.28* 
RALP 191 60.1 - 6.7* - - - 1.23* 
Ryu[114], 2013 
Department of Urology, Asan 
Medical Center, University of 
Ulsan College of Medicine, Seoul Korea 
RRP 340 64.9 24.7 9.7 36.2 170.8 - 10.1* 
RALP 524 64.9 24.6 10.1 36 146.4 - 7.9* 
Froehner[102], 
2013 
Departments of a Urology University 
Hospital ‘Carl Gustav Carus’, 
RRP 2,438 64.9*  10.4* - - - 7.7 
RALP 317 62.6*  6.4* - - - 8.0 
Sammon[115], 
2013 
Multi- centers  
RRP 28,054 - - - - - - - 
RALP 49,562 - - - - - - - 
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Vora [116], 2013 Multi- centers 
RRP 95 60.3  9.1 - - - -- 
RALP 140 62.1  8.3 - - - -- 
Alemozaffar[117], 
2014 
Department of Urology, Emory 
University School of Medicine, Atlanta, 
GA, USA; 
RRP 621 65.4* 26.0* 5.6* 52.6 - - 2.9* 
RALP 282 67.2* 26.4* 5.0* 55.8  - 1.8* 
Gagnon[118], 
2014 
The Vancouver Prostate Centre and 
Department of Urologic Sciences, 
University of British Columbia, 
Vancouver, BC 
RRP 200 64.7 27.2 11.2 35.2 114.2* - 2* 
RALP 200 64.2 27.2 6.6 36.9 233.6* - 1.7* 
Wallerstadt[103], 
2015 
Multi- centers 
RRP 778 63 26.2 6.2 - 103* - 4.1* 
RALP 1847 63 25.9 6.1 - 175* - 3.3* 
Our study 
Department of Urology and Pediatric 
Urology, University Hospital, Kiel, 
Germany. 
RRP 187 67.7 27.3 8.7* 41.6 269.5* 4.4 13.5* 
RALP 98 68.1 26.8 7.4* 45.4 331.3* 3.9 9.7* 
*p ˂ 0.05 
! Pre or postoperative prostatic volume  
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Table 19: (Cont.) 
First author No. of cases, type 
Transfusion 
rate, % 
Catheterisation 
duration, d 
Overall PSM, % Overall complication rate, % 
Menon[104], 2002 
RRP 30 17* 13.7* 29 36.7 
RALP 30 7* 10.7* 26 26.7 
Tewari[105], 2003 
RRP 100 67* 15.8* 23* 20* 
RALP 200 0* 7* 6* 2.5* 
Ahlering[106], 2004 
RRP 60 2 9 12 10 
RALP 60 0 7 16.7 6.7 
Nelson[107], 2007 
RRP 374 - - - 15 
RALP 629 - - - 17 
Smith[108], 2007 
RRP 200 - - 35.5* - 
RALP 200 - - 15* - 
Fracalanza[109], 2008 
RRP 26 - - 23 - 
RALP 37 - - 28.6 - 
Ficarra, [110]2008 
RRP 105 - - - 13 
RALP 103 - - - 10 
Krambeck[111], 2009 
RRP 588 - - 38.1 - 
RALP 294 - - 32.7 - 
Hohwü[112], 2009 
RRP 147 - - - - 
RALP 127 - - - - 
Mirza[113], 2011 
RRP 180 - - 28.9 - 
RALP 191 - - 13.6 - 
Ryu[114], 2013 
RRP 340 42.2* 7.5* - 68 
RALP 524 6.3* 6.2* - 27.3 
Froehner[102], 2013 
RRP 2,438 10.4 - - 45.3 
RALP 317 8.9 - - 24 
Sammon[115], 2013 
RRP 28,054 - - - 12.7 
RALP 49,562 - - - 8.6 
Vora [116], 2013a 
RRP 95 - -- 58.9 - 
RALP 140 - -- 47.1 - 
Alemozaffar[117], 2014 
RRP 621 30.3* - 23.1 - 
RALP 282 4.3* - 24.5 - 
 
Gagnon[118], 2014 
 
RRP 200 1.5 - 31 11.5* 
RALP 200 3.5 - 24.6 22* 
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Wallerstadt[103], 2015 
RRP 778 - - - 80.5* 
RALP 1847 - - - 70.1
*
 
Our study 
RRP 187 7.1 12.6* 36.6* 59.9* 
RALP 98 6.1 9.2* 21.4* 39.8* 
*p ˂ 0.05 
a for locally advanced PCa 
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5.4 Complications. 
Many complications have been reported after RP with an overall intra- and postoperative 
incidence of 54% (own data). The complications were as follows:  
5.4.1 Intraoperative vascular injuries  
Vascular injuries are a potentially devastating complication of RP. They may occur in the 
initial stages of the operation, such as when gaining access to the abdominal cavity in RALP 
and LRP, or during PNLD. The most common intraoperative problem is bleeding, usually 
arising from venous structures and the key to avoiding them is through careful dissection and 
by avoiding tunnel-like operating fields limiting visualization and access to surrounding 
structures. It is important to recognize such injuries promptly and to manage them 
immediately [119–121]. The incidence of detected intraoperative vascular injuries in our data 
was 1.1%; 3 cases who underwent RALP were managed intraoperatively by hemostatic suture 
without open conversion and/or postoperative problems. 
5.4.2 Rectal injury 
Regardless of the approach, rectal injury is a possible complication of RP because of the close 
anatomical relationship between the rectum and the prostate [122]. The incidence of rectal 
injury ranges between 0.7 and 2.4%. Intraoperative detection and repair of the injury is crucial 
[67]. Multi-layered primary closure and interposition of omentum between the rectum and 
anastomosis with or without proximal ileostomy usually avoids long-term problems [119]. 
The incidence of rectal injury in our study was 1.4%; two cases (one case for each RALP and 
RRP) were discovered intraoperatively and treated with primary closure and safety proximal 
iliostomy and other two cases of RRP incomplete rectal injury was discovered 
intraoperatively and treated only with primary closure and postoperative total parenteral 
nutrition.  
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5.4.3 Anastomotic insufficiency or prolonged catheterization time  
Failure to achieve a watertight closure of the anastomosis can result in urinary extravasations 
and accumulation of urine, even if a pelvic drain is placed [67]. The catheter may be removed 
3 to 21 days after surgery, depending on the integrity and the amount of tension on the vesico-
urethral anastomosis, its removal before 7 days is associated with a 15% to 20% risk of 
urinary retention. After the catheter has been removed, Kegel exercises should be initiated and 
a protective pad used until complete urinary control is achieved [56]. On the 7
th
 postoperative 
day, a cystogram was performed to evaluate the vesico-urethral anastomosis in both RRP and 
RALP cases; if there was no leakage in the cystogram, the catheter was removed. Table 20 
demonstrates the different postoperative periods after which the catheter was removed and the 
correlating number and percentage of cases in RRP and RALP. 
Table 20: The number and percentage of the our cases by which the catheter was removed 
different postoperative days 
Catheterization time RALP,% RRP,% P Value 
7 days or less 73 (76%) 89 (48.4%) ˂ .0001 
8 to 10 7 (7.3%) 26 (14.1%)  
11 to 14 0 17 (9.2%)  
15-21 11 (11.5%) 30 (16.3%)  
>21 5 (5.2%) 22 (12%)  
Fisher’s exact test                                                                              * Statistical significant difference (P < 0.05) 
Anastomotic insufficiency is usually treated by prolonged catheterization; 45 patients (15.8%, 
10 cases RALP and 35 cases RRP) were treated with prolonged catheterization of up to 36 
days in RALP and 69 days in RRP. In some rare cases, leakage requires more invasive 
intervention such as bilateral percutaneous nephrostomy (PCN) or urethra-cystoscopy (UC) to 
evaluate the anastomotic area; PCN and UC were done in one RRP patient each. 
5.4.4 Hemorrhagic (delayed bleeding) complications  
Significant bleeding after RP is defined as postoperative hemorrhage requiring acute 
transfusion of blood to support blood pressure; a patient who requires acute transfusions for 
hypotension after RP within the pelvis should be explored to evacuate the pelvic hematoma to 
decrease the risk of bladder neck contracture and incontinence [119]. The incidence of 
postoperative hemorrhagic complications was 1.4% “own data” (4 cases: 3 RALP and one 
RRP). These patients presented with postoperative bleeding and pelvic or retroperitoneal 
hematoma that needed immediate surgical evacuation under general anesthesia ± bilateral 
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immobilization of the internal iliac arteries. One RALP patient presented with a subcutaneous 
hematoma and small pelvic hematoma, which was treated conservatively. 
5.4.5 Postoperative voiding difficulties  
Urethral stricture formation is a known complication of RP with a reported incidence of 0.4% 
to 32%. These strictures most commonly occur at the bladder neck and arise from inadequate 
approximation during surgery, urinary extravasation, or distraction of the bladder neck from a 
hematoma; this causes should be considered in any patient who complains of a poor urinary 
stream or in patients who have prolonged and unaccountable incontinence [119,123]. Two 
patients (0.7%, one case in RRP and RALP each) developed micturition difficulties within 3 
months postoperatively; they were treated by transurethral resection of the anastomotic area 
under general anesthesia. 
5.4.6 Lymphoceles  
A lymphocele, also known as a lymphocyst, is a collection of lymphatic fluid occurring in 
consequence of surgical dissection and inadequate closure of the afferent lymphatic vessels. 
PLND is a technically challenging surgery and can be associated with higher rates of intra- 
and/ or postoperative complications. Lymphoceles are the most frequent postoperative 
complications after PLND and the risk of lymphocele development is usually affected by the 
extent of PLND and by the choice of surgical access (transperitoneal or extraperitoneal) 
[124].  
Lymphoceles are often incidentally found during routine sonographic examination; however 
they may also cause clinical symptoms. The point of necessary intervention is still not clearly 
defined and asymptomatic lymphoceles usually do not require drainage or treatment; larger of 
lymphoceles may compress the bladder or the external iliac vein and infected lymphoceles 
may also need treatment. Percutaneous drainage with or without injection of a sclerosing 
agent, or laparoscopic opening of a window with marsupialization of the lymphocele are 
typically successful measures [67].  
Despite the extraperitoneal access of the RRP with standard peritoneal fenestration to avoid 
lymphoceles, 34 patients (11.9%, 26 RRP and 8 RALP cases) presented with postoperative 
lymphoceles. 18 cases (6.3%, 15 RRP and 3 RALP cases) were treated by laparoscopic 
peritoneal fenestration, 6 cases (3 RRP and 3 RALP cases) were treated by US- / CT- guided 
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pig tail insertion (drain) and 10 cases (3.5%, 8 RRP and 2 RALP cases) were treated by 
conservative management. 
5.4.7 Thrombo-embolic complications 
Thrombophlebitis with pulmonary embolism is a life-threatening complication and a major 
cause of mortality after RP. A recent population-based report estimated the rates of thrombo-
embolic events after RP between 2.9% and 3.9% irrespective of the surgical approach and 
despite routine use of prophylaxis, it is still associated with a substantially higher risk of 
mortality than other complications [125,126] . Several risk factors increase thrombo-embolic 
events after RP such as advanced age, comorbidities like cardiopulmonary disease, a prior 
history of DVT, more advanced PCa and simultaneous PLND [127].  
Measures to prevent this complication include careful positioning on the operating room table 
to avoid compression of the veins in the lower extremity, early ambulation and low-dose low-
molecular-weight heparin which is used at some centers. Most importantly, patients should be 
informed of the potential signs and symptoms of this complication before they go home and 
should be instructed to call the physician immediately if they have any of the following 
symptoms: swelling or pain in the leg, especially in the calf; sudden chest pain thatworsens on 
taking a deep breath; hemoptysis; shortness of breath; or a sudden onset of weakness or 
fainting [119]. In our study, five cases (1.8%) developed postoperative thrombo-embolic 
complications, one RRP case developed massive pulmonary embolism postoperative and was 
admitted in ICU. Two RRP cases developed postoperative DVT, which was treated by 
anticoagulant therapy and two cases (RRP and RALP one each) developed a postoperative 
cerebral stroke, which was treated by anticoagulant therapy with development of neurological 
affections. 
5.4.8 Urinary tract infections  
Urinary tract infections (UTIs) together with pneumonia are most common type of healthcare-
associated infection, after SSIs and account for more than 15 % of infections reported by 
acute care hospitals [128]. Urinary tract infections can manifest as bacteriuria with limited 
clinical symptoms, sepsis or severe sepsis, depending on localised or systemic extension 
[129].  
 
 Discussion  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
54 
 
Criteria for postoperative urinary tract infections (UTI) vary by organization, medical 
specialty and even within hospitals. However, in AUA white paper for catheter-associated 
urinary tract infections show the definitions and symptoms must be present in the patient to 
meet the diagnosis (Table 21) [130]. In our study, seven cases (2.5%, 2 RALP and 5 RRP 
cases) showed a positive urinary culture of >10
5
 colonies/mL urine and were treated with 
intravenous antibiotics.  
Table 21: Postoperative symptomatic urinary tract infection must meet one of the following 
two criteria [130]. 
One of the following: fever (>38°C), 
urgency, frequency, dysuria, or 
suprapubic tenderness  
And Urine culture of >105 colonies/mL urine 
with no more than two species of organisms  
Two of the following: fever (>38°C), 
urgency, frequency, dysuria, or 
suprapubic tenderness  
 
And  Any of the following:  
 Dipstick test positive for leukocyte 
esterase and/or nitrite  
 Pyuria (>10 WBCs/mL or >3 WBC/hpf of 
unspun urine)  
 Organisms seen on Gram stain of unspun 
urine  
 Two urine cultures with repeated isolation 
of the same uropathogen with >102 
colonies/mL urine in non-voided 
specimen  
 Urine culture with <105 colonies/mL 
urine of single uropathogen in patient 
being treated with appropriate 
antimicrobial therapy  
 Physician's diagnosis  
 Physician institutes appropriate 
antimicrobial therapy  
 
5.4.9 Surgical site infections  
SSI the most common type of healthcare-associated infections; its morbidity is not limited to 
the physical discomfort of the wound, impaired cosmetics, or prolonged time to recovery. 
Patients who develop an SSI are about 60% more likely to spend time in an intensive care 
unit, 5 times more likely to be readmitted to the hospital or to have longer hospitalizations, 
substantial increases in costs of care and twice more likely to have the incidence of a 30-day 
mortality than patients who do not develop an SSI [131,132]. 
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In his 2011 paper, Tollefson shows that patients undergoing RARP had lower rates of SSI 
than similar patient cohorts undergoing RRP (0.6% vs. 4.7%; P= .001) [132]. In our study, 19 
patients (6.7%) developed SSIs (17 RRP and 2 RALP cases). Of these, 13 (4.6%) RRP cases 
developed postoperative SSI and wound dehiscence (deep incisional SSIs), which were 
treated by repeated changing of the Vacuum Assisted Closure system (VAC), three cases 
(1.1%, one RRP and two RALP cases) developed infected lymphoceles (space / organ SSIs) 
that were treated either with CT / US-guided pig tail insertion or surgical evacuation and 
lavage and three RRP cases (1.1%) developed postoperative SSIs that could be treated with 
local measures (superficial incisional SSI). 
5.4.10 Postoperative ileus  
Postoperative ileus is a frequent complication of abdominal surgery and is defined as a 
temporary impairment of gastrointestinal motility after surgery. Despite the advances in 
surgical techniques and preoperative care for abdominal pathologies, postoperative ileus is a 
common complication after abdominal surgery [133]. Although the results of post-RP ileus 
vary, the incidence ranges from 5–25% thus prolonging the duration of the hospital stay, 
reducing patient satisfaction and increasing the overall costs [134]. The postoperative ileus is 
traditionally accepted as a physiological response to abdominal surgery, although several 
etiologies, such as physiological response to surgical trauma, visceral manipulation, intra– 
and/or postoperative complications and postoperative opiate usage [134]. 
The point at which the postoperative ileus becomes abnormally prolonged has not been 
clearly established. It normally resolves within approximately four days after an abdominal 
surgical procedure; however, it may last 2 days or less following laparoscopic surgery and 
may continue for more than one week after major laparotomies [135]. In our study, 6 cases 
(2.1%, 4 RRP and 2 RALP cases) developed a post postoperative ileus that lasted more than 4 
days and could only be resolved by medical treatment.  
5.4.11 Blood or fresh frozen plasma transfusion  
RP is associated with an elevated potential for intraoperative blood loss that may lead to the 
necessity for blood transfusion. The transfusion rates at tertiary care centers range from 3% to 
67%, irrespective of the transfusion type and surgical approach [136]. However, the shift from 
RRP to minimally invasive RP may result in fewer bleeding complications thereby reducing 
the overall need for blood transfusions; however a significant blood loss during RP remains 
problem [137,138]. The incidence of postoperative transfusion of packed RBCs and FFP was 
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20 cases (7%, 14 RRP and 6 RALP) which needed postoperative transfusion either of 
erythrocyte concentrate, FFP and/or platelet concentrate, ranging from 2 to 10 units of 
erythrocyte concentrate. 
5.4.12 Ureteral injury or stricture 
Ureteral injury or stricture is an uncommon complication. It is more likely to occur in patients 
with a large prostate, a prior history of prostatitis, a large median lobe, previous prostate 
procedures and it can occur both as intravesical ureteral injury, i. e. during dissection of the 
posterior bladder neck or as extra-vesical ureteral injury, i. e. during lateral dissection of the 
peritoneal reflection for creation of the extra-peritoneal space; in addition, the ureter may be 
injured as it might be mistaken for the vas deferens and less commonly, it could be e injured 
during PLND [139]. 
Prevention of ureteral injury is best accomplished by careful identification of anatomic 
landmarks and template-oriented systematic PLND with defined boundaries and through pre- 
or intraoperative placement of ureteral catheters for patients who are at risk for ureteral injury. 
Furthermore, cystoscopic examination can be used to delineate the bladder neck and the 
ureteral orifice anatomy in patients with large median lobes during or prior RP [140,141]. In 
our study, he incidence of ureteral injury and postoperative ureteral stricture was two cases 
(0.7%, both RRP), one occurred intraoperatively as a ureteral injury due to marked 
retroperitoneal fibrosis and was treated by primary closure and insertion of a JJ stint, which 
was removed one month after the operation and in the other case the patient developed a 
ureteral stricture two months postoperatively requiring re-exploration and re-implantation of 
the ureter into the bladder. 
5.4.13 Conversion to an Open Procedure  
Converting from a minimally invasive approach to an open procedure should not be 
considered a complication it itself, but the conversion is more likely to be performed in the 
presence of a complication [139]. Open conversion is rare (<2%) and has been cited in the 
literature as occurring usually during a surgeon’s early experience with LRP or RALP, mainly 
as a result of a failure to progress or uncertainty of dissection planes. The patient must be 
informed about this possibility [142]. Appropriate judicious decision-making regarding open 
conversion can actually prevent a complication. In our study, open conversion occurred only 
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in one case (0.35%) during the early learning curve and in a 2
nd
 patient due to intraoperative 
technical difficulties, bleeding and rectal injury. 
5.4.14 Death  
Death after surgery is a clinically important outcome measure for surgeons, patients, policy-
makers and health-service researchers and is increasingly being used as an indicator of quality 
for major surgical procedures [143]. Death within 30 days after RP is relatively uncommon 
and occurs in <1% of patients; it is affected by the age of the patient and possible 
comorbidities. The most common causes of death are cardiovascular events, such as 
myocardial infarction and pulmonary embolism [144,145]. In our series, two patients (0.7%, 
both RRP) died during the early postoperative course: one died on the first postoperative day 
due to cardiogenic shock and the other died within the first two postoperative weeks due to 
massive pulmonary embolism. 
5.5 Learning curve. 
Despite the learning curve of our surgeons, the perioperative outcome of RALP was more 
favorable than that of RRP; the patients who underwent RALP had shorter catheterization and 
hospitalization times and lower overall complications rates, as well as lower rates of 
anastomotic insufficiency, lymphoceles and SSIs. Moreover, our RALP results are 
comparable to most other contemporary series (Table 22). 
In order to evaluate the learning curve of RALP, we compared the perioperative outcome of 
the initial 50 cases (Group I) and the subsequent 48 cases (Group II). Here we found a clear 
decrease in the mean operating time (340.7 ± 59.4 vs. 321.5 ± 53.5 min., p = .192), 
catheterization time (9.3 ± 5.5 vs. 9.1 ± 5.6 days, p = .931) and a significant decrease in 
hospitalization time (10.2 ± 4.2 vs. 9.1 ± 2.3 days, p = .038).  
The absence of standardized reporting of surgical complications for RP lead to a wide 
variation in the types of complications reported as well as in the overall incidence of 
complications. In Table 22, we try to summarize the incidence of various complications in 
studies comparing RRP and RALP. From this Table we may conclude that the incidence of 
perioperative complications in our patients was comparable with others in the literature, e. g. 
rectal injury and UTIs, however, there was a greater tendency for postoperative lymphceles 
and SSIs in RRP patients and lesser tendency for postoperative urinary difficulties and ileus.  
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Several authors have started using the Clavien- Dindo classification system to describe 
complications associated with minimally-invasive RP [71]. In Table 23 we compare our 
complications results with respect to the Clavien classification to those of other studies 
comparing RRP and RALP. The comparison shows our patients to be more likely to have 
major complications than other studes, especially grade IIIb patients in both groups. 
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Table 22: Incidence of various complications in the studies compares RRP and RALP. 
First author 
No. of 
cases, 
type 
Vascular 
injuries, 
% 
Rectal 
injury, 
% 
Uretric 
injury or 
stricture, 
% 
Urinary 
leakage, 
% 
Hemorrhagic 
complications, 
clot retention 
% 
Postoperative 
infection 
fevers, % 
Lymphocele, 
% 
Ileus, 
% 
Thrombo-
embolic 
complication, 
% 
SSIs, 
% 
Open 
Conversion, 
% 
Postoperative 
urinary 
difficulty, or 
retention % 
Death,% 
Overall 
complication 
rate, % 
Menon[104], 
2002 
RRP 30 - 3 - - - - - 9 - 1 - 3 0 36.7 
RALP 30 - 0 - - - - - 9 - 1 3 3 0 26.7 
Tewari[105], 
2003 
RRP 100 - 1 - - 4 4* 2 3 2 1 - - - 20* 
RALP 
200 
- 0 - - 0.5 - 0 1.5 0.5 1 0 - - 2.5* 
Nelson[107], 
2007 
RRP 374 - 0 - 1 1.2 2.1 1.4 4.1 0.5 1.4 - 1 - 15 
RALP 
629 
- 0.15 - 2.4 2 2.3 0.3 4.2 1.15 0.3 - 0.3 - 17 
Ficarra, 
[110]2008 
RRP 105 - 0 - - 7 - - 1 2 1 - - - - 
RALP 
103 
- 2 - - 7 - - 1 0 0 - - - - 
Krambeck[111], 
2009 
RRP 588 - - 0.2 - 1.8 1.3 1.9 - 4.2 - - 7.7 - - 
RALP 
294 
- - 0 - 3.5 1 1.1 - 2 - - 7.9 - - 
Ryu[114], 2013 
RRP 340 - - - 10* - - - - - 4.1* - 7* - - 
RALP 
524 
- - - 2.1* - - - - - 0.2* - 2.7* - - 
Froehner[102], 
2013 
RRP 
2,438 
- - - - - - 26.1* - 3.2 3.2 - - 0.04 45.3 
RALP 
317 
- - - - - - 30.9* - 2.5 2.5 - - 0.3 24 
Sammon[115], 
2013 
RRP 
28,054 
- - - - - - - - - - - - 0.1 12.7 
RALP 
49,562 
- - - - - - - - - - - - 0 8.6 
Wallerstadt[103], 
2015 
RRP 778 - - - - 13.8 12.6 - 11.2 2.8 5.6 - - - 80.5* 
RALP 
1847 
- - - - 11.8 15.3 - 7.8 0.6 3.3 - - - 70.1* 
Our study 
RRP 187 0 1.6 1.2 20 0.5 3.2 13.9 2.2 2.2 9.2 - 0.5 1 59.9* 
RALP 98 3.1 1 0 10.2 4 2 8.1 2 1 2 1 1 0 39.8* 
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Table 23: The percentage Clavien classification system of complications in the studies compares RRP and RALP. 
First author No. of cases, type I, % II, % IIIa, % IIIb, % IV, % V, % 
Ryu[114], 2013 
RRP 340 16.1 44.4 2.9 4.4 0.3 - 
RALP 524 16 7.8 2.1 0.8 0.6 - 
Gagnon[118], 
2014 
RRP 200 5.5 3 2 1 0 0 
RALP 200 13 7 1.5 0.5 0 0 
Our study 
RRP 187 25.7 11.8 2.1 18.1 1.1 1.1 
RALP 98 18.4 8.1 5.1 7.1 0 0 
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6. Summary and conclusion: 
The DaVinci robotic surgery system offer numerous advantages providing improved 
visualization, increased dexterity, restored proper hand-eye coordination, ergonomic work 
position of the surgeon and it offers 3D images with 12-fold magnification. This provides a 
mode of vision allowing for meticulous dissection procedures. As the camera is controlled by 
the surgeon, he/she can maintain a stable, optimal view of the surgical field without concern 
for the camera-driver. This study represents a retrospective case series of patients who were 
treated with RP, either RRP or RALP) for a confirmed PCa over the last 4 years in the 
Department of Urology and Pediatric Urology of the University Hospital Schleswig-Holstein, 
Campus Kiel, Germany. 285 patients were included in this study, 98 of these were treated 
with RALP and 187 with RRP. In January 2013, the first cases of RALP were performed and 
from that time the majority of patients underwent RALP as the patient numbers undergoing 
RRP decreased rapidly down to only five cases in 2014 and no cases in 2015. 
The age of the patients included in this study was 68.1 ± 6.7 years (range: 47-85), BMI 27.2 ± 
3.8 kg/m
2
 (range: 19.5-42.4) and the preoperative prostate size was 42.9 ± 21.2 cm
3
 (range: 
12-160). Patients who underwent RALP were more likely to have nerve sparing procedures 
(82.7% vs. 47.1%, p ˂ .0001). However, the operating time in these patients was longer 
(331.3 min. vs. 269.5 min, p ˂ .0001). The oncological data show that more than 50% of the 
patients who underwent RP had a pathological tumor stage (pT2) and the patients who 
underwent RALP were less likely to have metastases in the LN drainage system or positive 
surgical margin. The overall complication rate was 54% (154/285) and despite the learning 
curve of our surgeons patients who underwent RALP were less likely to have complications 
(39%, 38/98) compared to those who underwent RRP (62%, 115/187) and had a lower 
incidence of anastomotic insufficiency and SSIs than RRP patients, however they were more 
prone to haemorrhagic complications. The Clavien- Dindo Classification is an acceptable 
classification system to assess RP complications and it can be applied in our department not 
only for RP but also for all other surgical procedures. According to the Clavien- Dindo 
classification, the patients who underwent RALP were less likely to have minor complications 
than those with RRP (I 18/98 vs. 48/187; II 8/98 vs. 22/187) as well as major complications 
(III 12/98 vs. 38/187; IV 0/98 vs. 2/187 and V 0/98 vs. 2/187). 
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In conclusion:  
Our study shows that the short-term perioperative outcomes and complications of RP may be 
influenced by the applied surgical technique. RALP and RRP remain acceptable options for 
treatment of PCa. Taken together; our findings with colleagues’ published data show RALP to 
be an acceptable alternative to RRP with a lower risk of complications. However, patient 
characteristics and surgical experience are likely to impact the perioperative outcome and 
complication rates. 
 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
58 
 
7. References 
[1] Hammerich, K. H., Ayala, G. E., Wheeler, T. M. (2009): Prostate cancer. Anatomy of the 
prostate gland and surgical pathology of prostate cancer. Contemporary issues in cancer 
imaging, Cambridge University Press, Cambridge, UK, New York. 
[2] Dasgupta, P., Kirby, R. S. (2012): ABC of prostate cancer. Applied Anatomy of the 
Prostate. ABC series, Wiley-Blackwell, Oxford. 
[3] McNeal, J. E. (1981): The zonal anatomy of the prostate, Prostate, 2, 35–49. 
[4] Campbell, M. F., Walsh, P. C., Wein, A. J. (2012): Campbell-Walsh urology: Surgical 
Anatomy of the Retroperitoneum, Adrenals, Kidneys, and Ureters, ed. 10, Saunders Elsevier, 
Philadelphia, Pa. 
[5] Zaneveld, L. J., Tauber, P. F. (1981): Contribution of prostatic fluid components to the 
ejaculate. Prog Clin Biol Res, 75A, 265–277. 
[6] Caspritz, S., Cernaj, J., Ernst, A., Folkerts, J., Hansmann, J., Kranzhofer, K., Krieghoff-
Henning, E., Kunz, B., Penzkofer, A., Treml, K., Wittenberg, K. (2014): Cancer in Germany 
2009/2010, ed. 9. Gesundheitsberichterstattung für Deutschland, Robert Koch-Institut, Berlin. 
[7] Zeegers, M. P., Jellema, A., Ostrer, H. (2003): Empiric risk of prostate carcinoma for 
relatives of patients with prostate carcinoma: a meta-analysis. Cancer, 97, 1894–1903. 
[8] Coussens, L. M, Werb, Z. (2001): Inflammatory cells and cancer: think different! J. Exp. 
Med, 193, F23-6. 
[9] Chuang, A. Y., DeMarzo, A. M., Veltri, R. W., Sharma, R. B., Bieberich, C. J., Epstein, J. 
I. (2007): Immunohistochemical differentiation of high-grade prostate carcinoma from 
urothelial carcinoma. Am. J. Surg. Pathol, 31, 1246–1255. 
[10] Giovannucci, E., Ascherio, A., Rimm, E. B., Colditz, G. A., Stampfer, M. J., Willett, W. 
C. (1993): A prospective cohort study of vasectomy and prostate cancer in US men. JAMA, 
269, 873–877. 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
59 
 
[11] Giovannucci, E., Ascherio, A., Rimm, E. B., Colditz, G. A., Stampfer, M. J., Willett, W. 
C. (1993): A retrospective cohort study of vasectomy and prostate cancer in US men. JAMA, 
269, 878–882. 
[12] Dennis, L. K., Dawson, D. V., Resnick, M. I. (2002): Vasectomy and the risk of prostate 
cancer: a meta-analysis examining vasectomy status, age at vasectomy, and time since 
vasectomy. Prostate Cancer Prostatic Dis, 5, 193–203. 
[13] Campbell, M. F., Walsh, P. C., Wein, A. J. (2012): Campbell-Walsh urology: 
Epidemiology, Etiology, and Prevention of Prostate Cancer, ed. 10, Saunders Elsevier, 
Philadelphia, Pa. 
[14] Bostwick, D. G., Burke, H. B., Djakiew, D., Euling, S., Ho, S. M., Landolph, 
J., Morrison, H., Sonawane, B., Shifflett, T., Waters, D. J., Timms, B. (2004): Human prostate 
cancer risk factors. Cancer, 101, 2371–2490. 
[15] Velicer, C. M, Kristal, A., White, E. (2006): Alcohol use and the risk of prostate cancer: 
results from the VITAL cohort study. Nutr Cancer, 56, 50–56. 
[16] Campbell, M. F., Walsh, P. C, Wein, A. J. (2012): Campbell-Walsh urology: Early 
Detection, Diagnosis, and Staging of Prostate Cancer, ed. 10, Saunders Elsevier, Philadelphia, 
Pa. 
[17] Heidenreich, A., Bastian,  P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, 
T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., Mottet, N.: European Association of 
Urology. (2014): EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local 
treatment with curative intent-update 2013. Eur. Urol, 65, 124–137. 
[18] Richie,  J. P., Catalona, W. J., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, 
R. C., Dekernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., Waters, W. Bedford, M, 
Michael, T., Southwick, P. C. (1993): Effect of patient age on early detection of prostate 
cancer with serum prostate-specific antigen and digital rectal examination. Urology, 42, 365–
374. 
[19] Carvalhal, G. F, Smith, D. S., Mager, D. E, Ramos, C., Catalona, W. J. (1999): Digital 
rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. 
or less. J. Urol, 161, 835–839. 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
60 
 
[20] Mottet, N., Bellmunt, J., Briers, E., Bolla, M., Cornford, P. (2015): European Guidelines 
on Prostate Cancer: Epidemiology, aetiology and pathology. 
[21] Thompson, I. M., Pauler, D. K., Goodman, P. J, Tangen, C. M., Lucia, M. S., Parnes, H. 
L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., Crowley, J. J., Coltman, 
CA Jr. (2004): Prevalence of prostate cancer among men with a prostate-specific antigen level 
or =4.0 ng per milliliter. N. Engl. J. Med, 350, 2239–2246. 
[22] Eastham, J. A., Riedel, E., Scardino, P. T., Shike, M., Fleisher, M., Schatzkin, A., Lanza, 
E., Latkany, L., Begg, C. B. (2003): Variation of serum prostate-specific antigen levels: an 
evaluation of year-to-year fluctuations. JAMA, 289, 2695–2700. 
[23] Stephan, C., Klaas, M., Müller, C., Schnorr, D., Loening, S. A., Jung, K. (2006): 
Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 
frequently used assay combinations: an update. Clin. Chem, 52, 59–64. 
[24] Hara, R., Jo, Y., Fujii, T., Kondo, N., Yokoyoma, T., Miyaji, Y., Nagai, A. (2008): 
Optimal Approach for Prostate Cancer Detection as Initial Biopsy: Prospective Randomized 
Study Comparing Transperineal Versus Transrectal Systematic 12-Core Biopsy. Urology, 71, 
191–195. 
[25] Takenaka, A., Hara, R., Ishimura, T., Fujii, T., Jo, Y., Nagai, A., Fujisawa, M. (2008): A 
prospective randomized comparison of diagnostic efficacy between transperineal and 
transrectal 12-core prostate biopsy. Prostate Cancer Prostatic Dis, 11, 134–138. 
[26] Pinkstaff, D. M., Igel, T. C., Petrou, S. P., Broderick, G. A., Wehle, M. J., Young, P. R. 
(2005): Systematic transperineal ultrasound-guided template biopsy of the prostate: Three-
year experience. Urology, 65, 735–739. 
[27] Walz, J., Thomassin-Piana, J., Poizat, F., Brunelle, S., Salem, N., Gravis, G. (2012): 
2033 External validation of the anna/c-trus system regarding the correct identification of 
prostate cancer lesions in the diagnosis of prostate cancer, J Urol, 187, e820. 
[28] Braeckman, J., Autier, P., Garbar, C., Marichal, M. P., Soviany, C., Nir, R., Nir, 
D., Michielsen, D., Bleiberg, H., Egevad, L., Emberton, M. (2008): Computer-aided 
ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate 
cancer. BJU Int, 101, 293–298. 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
61 
 
[29] Hamann, M. F., Hamann, C., Trettel, A., Jünemann, K. P., Naumann, C. M. (2015): 
Computer-aided transrectal ultrasound: does prostate HistoScanning™ improve detection 
performance of prostate cancer in repeat biopsies? BMC Urol, 15, 76–83. 
[30] Moore, C. M., Kasivisvanathan, V., Eggener, S., Emberton, M., Fütterer, J. J., Gill , I. 
S., Grubb Iii, R. L., Hadaschik, B., Klotz, L., Margolis, D. J., Marks, L. S., Melamed, J., Oto, 
A., Palmer, S. L., Pinto, P., Puech, P., Punwani, S., Rosenkrantz, A. B., Schoots, I. G., Simon, 
R., Taneja, S. S., Turkbey, B., Ukimura, O., van der Meulen, J., Villers, A., Watanabe, Y. 
;START Consortium. (2013): Standards of reporting for MRI-targeted biopsy studies 
(START) of the prostate: recommendations from an International Working Group. Eur. Urol, 
64, 544–552. 
[31] Nicolas, V., Beese, M., Keulers, A., Bressel, M., Kastendieck, H., Huland, H. (1994): 
MR tomography in prostatic carcinoma: comparison of conventional and endorectal MRT. 
Rofo, 161, 319–326. 
[32] Hadaschik, B. A., Kuru, T. H., Tulea, C., Rieker, P., Popeneciu, I. V., Simpfendörfer, 
T., Huber, J., Zogal, P., Teber, D., Pahernik, S., Roethke, M., Zamecnik, P., Roth, W., Sakas, 
G.,Schlemmer, H. P., Hohenfellner, M. (2011): A novel stereotactic prostate biopsy system 
integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J. Urol, 
186, 2214–2220. 
[33] Wolf, J. S., Cher, M., Dall'Era, M., Presti, J. C., Hricak, H. C., Peter R. (1995): Original 
Articles: Prostate Cancer: The Use and Accuracy of Cross-Sectional Imaging and Fine Needle 
Aspiration Cytology for Detection of Pelvic Lymph Node Metastases Befor Radical 
Prostatectomy. J. Urol, 153, 993–999. 
[34] Bailey, D. L. (2005): Positron emission tomography: Basic sciences, Springer, New 
York. 
[35] Vali, R., Loidl, W., Pirich, C., Langesteger, W., Beheshti, M. (2015): Imaging of prostate 
cancer with PET/CT using (18) F-Fluorocholine. Am J Nucl Med Mol Imaging, 5, 96–108. 
[36] Osmonov, D. K., Heimann, D., Janßen, I., Aksenov, A., Kalz, A., Juenemann, K. P. 
(2014): Sensitivity and specificity of PET/CT regarding the detection of lymph node 
metastases in prostate cancer recurrence. Springerplus, 3, 340. 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
62 
 
[37] Picchio, M., Briganti, A., Fanti, S., Heidenreich, A., Krause, B. J., Messa, C., Montorsi, 
F., Reske, S. N., Thalmann, G. N. (2011): The role of choline positron emission 
tomography/computed tomography in the management of patients with prostate-specific 
antigen progression after radical treatment of prostate cancer. Eur. Urol, 59, 51–60. 
[38] Carlin, B. I., Andriole, G. L. (2000): The natural history, skeletal complications, and 
management of bone metastases in patients with prostate carcinoma. Cancer, 88, 2989–2994. 
[39] Brown, M. S., Chu, G. H., Kim, H. J., Allen-Auerbach, M., Poon, C., Bridges, 
J., Vidovic, A., Ramakrishna, B., Ho, J., Morris, M. J., Larson, S. M., Scher, H. I., Goldin, J. 
G. (2012): Computer-aided quantitative bone scan assessment of prostate cancer treatment 
response. Nucl Med Commun, 33, 384–394. 
[40] Brock, M., Noldus, J., Eggert, T. (2011): 2133 Comparison of real-time elastography to 
conventional grayscale ultrasound: what technique should be used to guide the systematic 
prostate biopsy? J. Urol, 185, e854. 
[41] Rørvik, J., Halvorsen, O. J., Servoll, E., Haukaas, S. (1994): Transrectal ultrasonography 
to assess local extent of prostatic cancer before radical prostatectomy. Br J Urol, 73, 65–69. 
[42] Hamann, M. F., Hamann, C., Schenk, E., Al-Najar A., Naumann, C. M., Jünemann, K. P. 
(2013): Computer-aided (HistoScanning) biopsies versus conventional transrectal ultrasound-
guided prostate biopsies: do targeted biopsy schemes improve the cancer detection rate? 
Urology, 81, 370–375. 
[43] Beheshti, M., Vali, R., Waldenberger, P., Fitz, F., Nader, M., Hammer, J., Loidl, 
W., Pirich, C., Fogelman, I., Langsteger, W. (2009): The use of F-18 choline PET in the 
assessment of bone metastases in prostate cancer: correlation with morphological changes on 
CT. Mol Imaging Biol, 11, 446–454. 
[44] de Jong, I. J., Pruim, J., Elsinga, P. H., Vaalburg, W., Mensink, H. J. (2003): 
Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl 
Med, 44, 331–335. 
[45] Evangelista, L., Cimitan, M., Zattoni, F., Guttilla, A., Zattoni, F., Saladini, G. (2015): 
Comparison between conventional imaging (abdominal-pelvic computed tomography and 
bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
63 
 
for the initial staging of patients with intermediate- to high-risk prostate cancer: A 
retrospective analysis. Scand J Urol, 1–9. 
[46] Humphrey, P. A. (2012): Histological variants of prostatic carcinoma and their 
significance. Histopathology, 60, 59–74. 
[47] Gleason, D. F., Mellinger, G. T. (1974): Prediction of prognosis for prostatic 
adenocarcinoma by combined histological grading and clinical staging. J. Urol, 111, 58–64. 
[48] Campbell, M. F., Walsh, P. C., Wein, A. J. (2012): Campbell-Walsh urology: Pathology 
of Prostatic Neoplasia, ed. 10, Saunders Elsevier, Philadelphia, Pa. 
[49] Sobin, L. H., Gospodariwicz, M., Wittekind, C. (eds) (2009): TNM classification of 
malignant tumors: UICC International Union Against Cancer, ed. 7, Wiley-Blackwell. 
[50] Mottet, N., Bellmunt, J., Briers, E., Bolla, M., Cornford, P. (2015): European Guidelines 
on Prostate Cancer: Classification and staging systems. 
[51] Mottet, N., Bellmunt, J., Briers, E., Bolla, M., Cornford, P. (2015) : European Guidelines 
on Prostate Cancer: Disease management. 
[52] Outwater, E. K., Petersen, R. O., Siegelman, E. S., Gomella, L. G., Chernesky, C. E., 
Mitchell, D. G. (1994): Prostate carcinoma: assessment of diagnostic criteria for capsular 
penetration on endorectal coil MR images. Radiology, 193, 333–339. 
[53] Harris, R. D., Schned, A. R., Heaney, J. A. (1995): Staging of prostate cancer with 
endorectal MR imaging: lessons from a learning curve. Radiographics, 15, 813-29; discussion 
829-32. 
[54] Jager, G. J., Ruijter, E. T., van de Kaa, C. A., de la Rosette, J. J., Oosterhof, G. O., 
Thornbury, J. R., Barentsz, J. O. (1996): Local staging of prostate cancer with endorectal MR 
imaging: correlation with histopathology. AJR Am J Roentgenol, 166, 845–852. 
[55] Young, H. H. (2002): The early diagnosis and radical cure of carcinoma of the prostate. 
Being a study of 40 cases and presentation of a radical operation which was carried out in 
four cases. 1905. J. Urol, 168, 914–921. 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
64 
 
[56] Campbell, M. F., Walsh, P. C., Wein, A. J. (2012) : Campbell-Walsh urology: Definitive 
Therapy for Localized Prostate Cancer: An Overview, ed. 10, Saunders Elsevier, 
Philadelphia, Pa. 
[57] Osmonov, D., Aksenov, A., Naumann, C., Hamann, M.F., Jünemann, K. P. (2014): 269 
Overall and cancer-specific survival in patients undergoing salvage extended pelvic lymph 
node dissection in recurrent prostate cancer, European urology supplements, 13, e269. 
[58] Eastham, J. A., Scardino, P. T., Kattan, M. W. (2008): Predicting an Optimal Outcome 
After Radical Prostatectomy: The Trifecta Nomogram. J. Urol, 179, 2207–2211. 
[59] Patel, V. R., Sivaraman, A., Coelho, R. F., Chauhan, S., Palmer, K. J., Orvieto, M. 
A., Camacho, I., Coughlin, G., Rocco, B. (2011): Pentafecta: A New Concept for Reporting 
Outcomes of Robot-Assisted Laparoscopic Radical Prostatectomy. Eur. Urol, 59, 702–707. 
[60] Oelrich, T. M. (1980): Anatomical dissections, Dept. of Anatomy, the University of 
Michigan, Medical School. 
[61] Reiner, W. G., Walsh, P. C. (1979): An anatomical approach to the surgical management 
of the dorsal vein and Santorini's plexus during radical retropubic surgery. J. Urol, 121, 198–
200. 
[62] Walsh, P. C., Donker, P. J. (1982): Impotence following radical prostatectomy: insight 
into etiology and prevention. J. Urol, 128, 492–497. 
[63] Hoznek, A., Menard, Y., Salomon, L., Abbou, C. (2005): Update on laparoscopic and 
robotic radical prostatectomy. Curr Opin Urol, 15, 173–180. 
[64] Abbou, C. C., Hoznek, A., Salomon, L., Lobontiu, A., Saint, F., Cicco, A., Antiphon, P., 
Chopin, D. (2000): Prostatectomie radicale laparoscopique réalisée à distance par robot. A 
propos d'un cas. Prog. Urol, 10, 520–523. 
[65] Albani, J. M. (2007): The role of robotics in surgery: a review. Mo Med, 104, 166–172. 
[66] Eichel, L., Ahlering, T. E., Clayman, R. V. (2004): Role of robotics in laparoscopic 
urologic surgery. Urol. Clin. North Am, 31, 781–792. 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
65 
 
[67] Campbell, M. F., Walsh, P. C., Wein, A. J. (2012) : Campbell-Walsh urology: 
Laparoscopic and Robotic- Assisted Laparoscopic Radical Prostatectomy and Pelvic 
Lymphadenectomy, ed. 10, Saunders Elsevier, Philadelphia, Pa. 
[68] Dindo, D., Clavien, P. (2008): What is a surgical complication? World J Surg, 32, 939–
941. 
[69] Mitropoulos, D., Artibani, W., Graefen, M., Remzi, M., Rouprêt, M, Truss, M. (2012): 
Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU 
guidelines panel assessment and recommendations. Eur. Urol, 61, 341–349. 
[70] Sokol, D. K., Wilson, J. (2008): What is a surgical complication? World J Surg, 32, 942–
944. 
[71] Dindo, D., Demartines, N., Clavien, P. (2004): Classification of surgical complications: a 
new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg, 
240, 205–213. 
[72] Anderson, D. J., Kaye, K. S. (2009): Staphylococcal surgical site infections. Infect. Dis. 
Clin. North Am, 23, 53–72. 
[73] Lawal, O. O., Adejuyigbe, O., Oluwole, S. F. (1990): The predictive value of bacterial 
contamination at operation in post-operative wound sepsis. Afr J Med Med Sci, 19, 173–179. 
[74] Reichman, D. E., Greenberg, J. A. (2009): Reducing surgical site infections: a review. 
Rev Obstet Gynecol, 2, 212–221. 
[75] Berard, F., Gandon, J. (1964): Postoperative wound infections: the influence of 
ultraviolet irradiation of the operating room and of various other factors. Ann. Surg, 160, 1–
192. 
[76] Mangram, A. J., Horan, T. C., Pearson, M. L., Silver, L. C., Jarvis, W. R. (1999): 
Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and 
Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect 
Control, 27, 97-132; quiz 133-4; discussion 96. 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
66 
 
[77] Meyer, E., Schröder, C., Gastmeier, P., Geffers, C. (2014) : The Reduction of 
Nosocomial MRSA Infection in Germany: An Analysis of Data From the Hospital Infection 
Surveillance System (KISS) Between 2007 and 2012, 111(19): 331-6. 
[78] Haley, R. W., Culver, D. H., Morgan, W. M., White, J. W., Emori, T. G., Hooton, T. M. 
(1985): Identifying patients at high risk of surgical wound infection. A simple multivariate 
index of patient susceptibility and wound contamination. Am. J. Epidemiol, 121, 206–215. 
[79] Tosoian, J. J., Loeb, S. (2012): Radical retropubic prostatectomy: comparison of the open 
and robotic approaches for treatment of prostate cancer. Rev Urol, 14, 20–27. 
[80] Novara, G., Ficarra, V., Rosen, R. C., Artibani, W., Costello, A., Eastham, J. 
A., Graefen, M., Guazzoni, G., Shariat, S. F., Stolzenburg, J. U., Van Poppel, H., Zattoni, 
F., Montorsi, F.,Mottrie, A., Wilson, T. G. (2012): Systematic Review and Meta-analysis of 
Perioperative Outcomes and Complications After Robot-assisted Radical Prostatectomy. Eur. 
Urol, 62, 431–452. 
[81] Klenk J, Rapp K, Büchele G, Keil, Ulrich, Weiland, Stephan K. (2007): Increasing life 
expectancy in Germany: quantitative contributions from changes in age- and disease-specific 
mortality. Eur J Public Health, 17, 587–592. 
[82] Calle, E. E., Rodriguez, C., Walker-Thurmond, K., Thun, M. J. (2003): Overweight, 
obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. 
Med, 348, 1625–1638. 
[83] Wiltz, A. L., Shikanov, S., Eggener, S. E., Katz, M. H., Thong, A. E., Steinberg, G. 
D., Shalhav, A. L., Zagaja, G. P., Zorn, K. C. (2009): Robotic radical prostatectomy in 
overweight and obese patients: oncological and validated-functional outcomes. Urology, 73, 
316–322. 
[84] Moskovic, D. J., Lavery, H. J., Rehman, J., Nabizada-Pace, F., Brajtbord, J., Samadi, D. 
B. (2010): High body mass index does not affect outcomes following robotic assisted 
laparoscopic prostatectomy. Can J Urol, 17, 5291–5298. 
[85] Zilberman, D. E., Tsivian, M., Yong, D., Albala, D. M. (2011): Surgical steps that 
elongate operative time in robot-assisted radical prostatectomy among the obese population. J. 
Endourol, 25, 793–796. 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
67 
 
[86] Pettus, J. A., Masterson, T., Sokol, A., Cronin, A. M., Savage, C., Sandhu, J. S., Mulhall, 
J. P., Scardino, P. T., Rabbani, F. (2009): Prostate size is associated with surgical difficulty 
but not functional outcome at 1 year after radical prostatectomy. J. Urol, 182, 949–955. 
[87] Levinson, A. W., Ward, N.T., Sulman, A., Mettee, L. Z., Link, R. E., Su, L. M., Christian 
P. (2009): The impact of prostate size on perioperative outcomes in a large laparoscopic 
radical prostatectomy series. J. Endourol, 23, 147–152. 
[88] Link, B. A., Nelson, R., Josephson, D. Y., Yoshida, J. S., Crocitto, L. E., Kawachi, M.  
H., Wilson, T. G. (2008): The impact of prostate gland weight in robot assisted laparoscopic 
radical prostatectomy. J. Urol, 180, 928–932. 
[89] Allaparthi, S. B., Hoang, T., Dhanani, N. N., Tuerk, I. A. (2010): Significance of prostate 
weight on peri and postoperative outcomes of robot assisted laparoscopic extraperitoneal 
radical prostatectomy. Can J Urol, 17, 5383–5389. 
[90] Martínez, C. H., Chalasani, V., Lim, D., Nott, L., Al-Bareeq, R. J., Wignall, G. R., Stitt, 
L., Pautler, S. E. (2010): Effect of prostate gland size on the learning curve for robot-assisted 
laparoscopic radical prostatectomy: does size matter initially? J. Endourol, 24, 261–266. 
[91] Skolarus, T. A., Hedgepeth, R. C., Zhang, Y., Weizer, A. Z., Montgomery, J. S., Miller, 
D. C., Wood, D. PJr., Hollenbeck, B. K. (2010): Does robotic technology mitigate the 
challenges of large prostate size? Urology, 76, 1117–1121. 
[92] Huang, A. C., Kowalczyk, K. J, Hevelone, N. D., Lipsitz, S. R., Yu, H. Y., Plaster, B. 
A., Amarasekara, C. A., Ulmer, W. D., Lei, Y., Williams, S. B., Hu, J. C. (2011): The Impact 
of Prostate Size, Median Lobe, and Prior Benign Prostatic Hyperplasia Intervention on Robot-
Assisted Laparoscopic Prostatectomy: Technique and Outcomes. Eur. Urol, 59, 595–603. 
[93] Ploussard, G., Briganti, A., de la Taille, A., Haese, A., Heidenreich, A., Menon, 
M., Sulser, T., Tewari, A. K., Eastham, J. A. (2014): Pelvic Lymph Node Dissection During 
Robot-assisted Radical Prostatectomy: Efficacy, Limitations, and Complications—A 
Systematic Review of the Literature. Eur. Urol, 65, 7–16. 
[94] Osmonov, D., Aksenov, A., Naumann, M., Jünemann, K.P. (2012): 781 Interval of 
freedom from biochemical relapse in patients with recurrent prostate cancer after salvage 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
68 
 
extended lymph node dissection. Experience at the Kiel University Hospital, European 
Urology Supplements, 11, e781. 
[95] Manfred, W., Lothar, W., Rolf, A., Winfried, A., Clemens, A. (2009): Multidisciplinary 
guideline of quality S3 for early detection, diagnosis and treatment of different stages of 
prostate cancer, 1st edn.: 5.Treatment of non-metastatic prostate cancer, ed. 1, Deutsche 
Gesellschaft für Urologie (DGU). 
[96] Patel, V. R. (2007): Robotic urologic surgery: Improving Outcomes for Early Return of 
Urinary Continence, Springer, London. 
[97] Wieder, J. A., Soloway, M. S. (1998): Incidence, etiology, location, prevention and 
treatment of positive surgical margins after radical prostatectomy for prostate cancer. J. Urol, 
160, 299–315. 
[98] Moore, B. M., Savdie, R., PeBenito, R. A., Haynes, A. M., Matthews, J., Delprado, 
W., Rasiah, K. K., Stricker, P. D. (2012): The impact of nerve sparing on incidence and 
location of positive surgical margins in radical prostatectomy. BJU Int, 109, 533–538. 
[99] Alkhateeb, S. S., Alibhai, S. M., Finelli, A., Fleshner, N. E., Jewett, M. A., Zlotta, A. 
R., Trachtenberg, J. (2010): Does nerve-sparing radical prostatectomy increase the risk of 
positive surgical margins and biochemical progression? Urol Ann, 2, 58–62. 
[100] Briganti, A., Capitanio, U., Abdollah, F., Gallina, A., Suardi, N., Bianchi, M., Tutolo, 
M., Salonia, A., Freschi, M., Rigatti, P., Montorsi, F. (2012): Assessing the risk of lymph 
node invasion in patients with intermediate risk prostate cancer treated with extended pelvic 
lymph node dissection. A novel prediction tool. Prostate, 72, 499–506. 
[101] Yossepowitch, O., Briganti, A., Eastham, J. A., Epstein, J., Graefen, M., Montironi, 
R., Touijer, K. (2014): Positive Surgical Margins After Radical Prostatectomy: A Systematic 
Review and Contemporary Update. Eur. Urol, 65, 303–313. 
[102] Froehner, M., Novotny, V., Koch, R., Leike, S., Twelker, L., Wirth, M. P. (2013): 
Perioperative complications after radical prostatectomy: open versus robot-assisted 
laparoscopic approach. Urol. Int, 90, 312–315. 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
69 
 
[103] Wallerstedt, A., Tyritzis, S. I., Thorsteinsdottir, T., Carlsson, S., Stranne, J., Gustafsson, 
O., Hugosson, J., Bjartell, A., Wilderäng, U., Wiklund, N. P., Steineck, G.,Haglind, E. (2015): 
Short-term Results after Robot-assisted Laparoscopic Radical Prostatectomy Compared to 
Open Radical Prostatectomy. Eur. Urol, 67, 660–670. 
[104] Menon, M., Tewari, A., Baize, B., Guillonneau, B., Vallancien, G. (2002): Prospective 
comparison of radical retropubic prostatectomy and robot-assisted anatomic prostatectomy: 
The Vattikuti Urology Institute experience. Urology, 60, 864–868. 
[105] Tewari, A., Srivasatava, A., Menon, M. (2003): A prospective comparison of radical 
retropubic and robot-assisted prostatectomy: experience in one institution. BJU Int, 92, 205–
210. 
[106] Ahlering, T. E., Woo, D., Eichel, L., Lee, D. I., Edwards, R., Skarecky, D. W. (2004): 
Robot-assisted versus open radical prostatectomy: a comparison of one surgeon's outcomes. 
Urology, 63, 819–822. 
[107] Nelson, B., Kaufman, M., Broughton, G., Cookson, M. S., Chang, S. S., Herrell, S. 
D., Baumgartner, R. G., Smith, J. A. Jr. (2007): Comparison of length of hospital stay 
between radical retropubic prostatectomy and robotic assisted laparoscopic prostatectomy. J. 
Urol, 177, 929–931. 
[108] Smith,  J. A. Jr., Chan, R. C., Chang, S. S., Herrell, S. D., Clark, P. E., Baumgartner, R., 
Cookson, M. S. (2007): A comparison of the incidence and location of positive surgical 
margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical 
prostatectomy. J. Urol, 178, 2385-9; discussion 2389-90. 
[109] Fracalanza, S., Ficarra, V., Cavalleri, S., Galfano, A., Novara, G., Mangano, 
A., Plebani, M., Artibani, W. (2008): Is robotically assisted laparoscopic radical 
prostatectomy less invasive than retropubic radical prostatectomy? Results from a 
prospective, unrandomized, comparative study. BJU Int, 101, 1145–1149. 
[110] Ficarra, V., Novara, G., Fracalanza, S., D'Elia, C., Secco, S., Iafrate, M., Cavalleri, 
S., Artibani, W. (2009): A prospective, non-randomized trial comparing robot-assisted 
laparoscopic and retropubic radical prostatectomy in one European institution. BJU Int, 104, 
534–539. 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
70 
 
[111] Krambeck, A. E., DiMarco, D. S., Rangel, L. J., Bergstralh, E. J., Myers, R. P., Blute, 
M. L., Gettman, M. T. (2009): Radical prostatectomy for prostatic adenocarcinoma: a 
matched comparison of open retropubic and robot-assisted techniques. BJU Int, 103, 448–
453. 
[112] Hohwü, L., Akre, O., Pedersen, K. V., Jonsson, M., Nielsen, C. V., Gustafsson, O. 
(2009): Open retropubic prostatectomy versus robot-assisted laparoscopic prostatectomy: a 
comparison of length of sick leave. Scand. J. Urol. Nephrol, 43, 259–264. 
[113] Mirza, M., Art, K., Wineland, L., Tawfik, O., Thrasher, J. (2011) : A Comparison of 
Radical Perineal, Radical Retropubic, and Robot-Assisted Laparoscopic Prostatectomies in a 
Single Surgeon Series, Hindawi Publishing Corporation. 
[114] Ryu, J., Kwon, T., Kyung, Y. S., Hong, S., You, D., Jeong, I. G., Kim, C. S. (2013): 
Retropubic versus robot-assisted laparoscopic prostatectomy for prostate cancer: a 
comparative study of postoperative complications. Korean J Urol, 54, 756–761. 
[115] Sammon, J. D., Karakiewicz, P. I., Sun, M., Sukumar, S., Ravi, P., Ghani, K. 
R., Bianchi, M., Peabody, J. O., Shariat, S. F., Perrotte, P., Hu, J. C., Menon, M., Trinh, Q. D. 
(2013): Robot-assisted versus open radical prostatectomy: the differential effect of 
regionalization, procedure volume and operative approach. J. Urol, 189, 1289–1294. 
[116] Vora, A. A., Marchalik, D., Kowalczyk, K. J., Nissim, H., Bandi, G., McGeagh, K. 
G., Lynch, J. H., Ghasemian, S. R., Verghese, M., Venkatesan, K., Borges, P., Uchio, E. 
M., Hwang, J. J. (2013): Robotic-assisted prostatectomy and open radical retropubic 
prostatectomy for locally-advanced prostate cancer: multi-institution comparison of oncologic 
outcomes, Prostate Int,1, 31–36. 
[117] Alemozaffar, M., Sanda, M., Yecies, D., Mucci, L. A., Stampfer, M. J., Kenfield, S. 
A. (2015): Benchmarks for Operative Outcomes of Robotic and Open Radical Prostatectomy: 
Results from the Health Professionals Follow-up Study. Eur. Urol, 67, 432–438. 
[118] Gagnon, L. O., Goldenberg, S. L., Lynch, K., Hurtado, A., Gleave, M. E. (2014): 
Comparison of open and robotic-assisted prostatectomy: The University of British Columbia 
experience. Can Urol Assoc J, 8, 92–97. 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
71 
 
[119] Campbell, M. F., Walsh, P. C., Wein, A. J. (2012): Campbell-Walsh urology: Radical 
Retropubic and Perineal Prostatectomy, ed. 10, Saunders Elsevier, Philadelphia, Pa. 
[120] Zorn, K. C., Katz, M. H., Bernstein, A., Shikanov, S. A., Brendler, C. B., Zagaja, G. 
P., Shalhav, A. L. (2009): Pelvic lymphadenectomy during robot-assisted radical 
prostatectomy: Assessing nodal yield, perioperative outcomes, and complications. Urology, 
74, 296–302. 
[121] Sotelo, R., Nunez Bragayrac, L. A., Machuca, V., Garza Cortes, R., Azhar, R. A. 
(2015): Avoiding and managing vascular injury during robotic-assisted radical prostatectomy. 
Ther Adv Urol, 7, 41–48. 
[122] de Arruda, H. O., Cury, J., Ortiz, V., Srougi, M. (2007): Rectal injury in radical 
perineal prostatectomy. Tumori, 93, 532–535. 
[123] Besarani, D., Amoroso, P., Kirby, R. (2004): Bladder neck contracture after radical 
retropubic prostatectomy. BJU Int, 94, 1245–1247. 
[124] Briganti, A., Chun, F. K., Salonia, A., Suardi, N., Gallina, A., Da Pozzo, L. 
F., Roscigno, M., Zanni, G., Valiquette, L., Rigatti, P., Montorsi, F., Karakiewicz, P. I. 
(2006): Complications and other surgical outcomes associated with extended pelvic 
lymphadenectomy in men with localized prostate cancer. Eur. Urol, 50, 1006–1013. 
[125] Hu, J. C., Gandaglia, G., Karakiewicz, P. I., Nguyen, P. L., Trinh, Q. D., Shih, Y. 
C., Abdollah, F., Chamie, K., Wright, J. L., Ganz, P. A., Sun, M. (2014): Comparative 
Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. Eur. 
Urol, 66, 666–672. 
[126] Alibhai, S. M., Leach, M., Tomlinson, G., Krahn, M. D., Fleshner, N., Holowaty, 
E., Naglie, G. (2005): 30-day mortality and major complications after radical prostatectomy: 
influence of age and comorbidity. J. Natl. Cancer Inst, 97, 1525–1532. 
[127] Schmitges, J., Trinh, Q. D., Sun, M., Abdollah, F., Bianchi, M., Budäus, L., Salomon, 
G., Schlomm, T., Perrotte, P., Shariat, S. F., Montorsi, F., Menon, M., Graefen, 
M., Karakiewicz, P. I. (2012): Venous thromboembolism after radical prostatectomy: the 
effect of surgical caseload. BJU Int, 110, 828–833. 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
72 
 
[128] Magill, S. S., Hellinger, W., Cohen, J., Kay, R., Bailey, C., Boland, B., Carey, D., de 
Guzman, J., Dominguez, K., Edwards, J., Goraczewski, L., Horan, T., Miller, M., Phelps, 
M.,Saltford, R., Seibert, J., Smith, B., Starling, P, Viergutz, B., Walsh, K., Rathore, 
M., Guzman, N., Fridkin, S. (2012): Prevalence of healthcare-associated infections in acute 
care hospitals in Jacksonville, Florida. Infect Control Hosp Epidemiol, 33, 283–291. 
[129] Grabe, M., Bjerklund-Johansen, T. E., Botto, H., Naber, M., Pickard, R. S., Tenke, P., 
Wagenlehner, F., Wullt, B. (2014): EAU guidelines on Urological Infections. Eur. Urol, 65, 
816–923. 
[130] Averch, T., Stoffel, J., Goldman, H., Griebling, T., Lerner, L.: AUA white paper on 
catheter-associated urinary tract infections: definitions and significance in the urologic patient 
[Internet], American Urological Association Education and Research. 
[131] Kirkland, K. B., Briggs, J. P., Trivette, S. L., Wilkinson, W. E., Sexton, D. J. (1999): 
The impact of surgical-site infections in the 1990s: attributable mortality, excess length of 
hospitalization, and extra costs. Infect Control Hosp Epidemiol, 20, 725–730. 
[132] Tollefson, M. K., Frank, I., Gettman, M. T. (2011): Robotic-assisted radical 
prostatectomy decreases the incidence and morbidity of surgical site infections. Urology, 78, 
827–831. 
[133] Lubawski, J., Saclarides, T. (2008): Postoperative ileus: strategies for reduction. Ther 
Clin Risk Manag, 4, 913–917. 
[134] Ozdemir, A. T., Altinova, S., Koyuncu, H., Serefoglu, E. C., Cimen, I. H., Balbay, D. 
M. (2014): The incidence of postoperative ileus in patients who underwent robotic assisted 
radical prostatectomy. Cent European J Urol, 67, 19–24. 
[135] Kim, M. J., Min, G. E., Yoo, K. H., Chang, S. G., Jeon, S. H. (2011): Risk factors for 
postoperative ileus after urologic laparoscopic surgery. J Korean Surg Soc, 80, 384–389. 
[136] Ficarra, V., Novara, G., Rosen, R. C., Artibani, W., Carroll, P. R., Costello, A., Menon, 
M., Montorsi, F., Patel, V. R., Stolzenburg, J. U., Van der Poel, H., Wilson, T. G., Zattoni, 
F.,Mottrie, A. (2009): Retropubic, Laparoscopic, and Robot-Assisted Radical Prostatectomy: 
A Systematic Review and Cumulative Analysis of Comparative Studies. Eur. Urol, 55, 1037–
1063. 
References  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
73 
 
[137] Schmitges, J., Sun, M., Abdollah, F., Trinh, Q. D., Jeldres, C., Budäus, L., Bianchi, 
M., Hansen, J., Schlomm, T., Perrotte, P., Graefen, M., Karakiewicz, P. I. (2012): Blood 
Transfusions in Radical Prostatectomy: A Contemporary Population-based Analysis. Urology, 
79, 332–338. 
[138] Chang, S. S., Duong, D. T., Wells, N., Cole, E. E., Smith, J. A. Jr., Cookson, M. S. 
(2004): Predicting blood loss and transfusion requirements during radical prostatectomy: the 
significant negative impact of increasing body mass index. J. Urol, 171, 1861–1865. 
[139] Yates, K., Sawczuk, S., Munver, R. Internet article: Complications of Laparoscopic and 
Robotic Radical Prostatectomy - The 3rd Edition: Prevention & Management: Complications 
of Laparoscopic and Robotic Pelvic Lymph Node Dissection | Main | Complications of 
Laparoscopic and Robotic Surgery in Pediatrics.  
[140] Gonzalgo, M. L., Pavlovich, C. P., Trock, B. J., Link, R. E., Sullivan, W., Su, L. M. 
(2005): Classification and trends of perioperative morbidities following laparoscopic radical 
prostatectomy. J. Urol, 174, 135–139. 
[141] Osmonov, D. K., Aksenov, A. V., Boller, A., Kalz, A., Heimann, D., Janssen, 
I., Jünemann. K. P. (2014): Extended salvage pelvic lymph node dissection in patients with 
recurrent prostate cancer. Adv Urol, 2014, 321619. 
[142] Bhayani, S. B., Pavlovich, C. P., Strup, S. E., Dahl, D. M., Landman, J., Fabrizio, M. 
D., Sundaram, C. P., Kaouk, J. H., Su, L. M. (2004): Laparoscopic radical prostatectomy: a 
multi-institutional study of conversion to open surgery. Urology, 63, 99–102. 
[143] Fink, A. S., Campbell, D. A. Jr., Mentzer, R. M. Jr., Henderson, W. G., Daley, 
J., Bannister, J., Hur, K., Khuri, S. F. (2002): The National Surgical Quality Improvement 
Program in non-veterans administration hospitals: initial demonstration of feasibility. Ann. 
Surg, 236, 344-53; discussion 353-4. 
[144] Alibhai, S. M., Leach, M., Tomlinson, G., Krahn, M. D., Fleshner, N., Naglie, G. 
(2006): Rethinking 30-day mortality risk after radical prostatectomy. Urology, 68, 1057–
1060. 
[145] Alibhai, S. M., Shabbir, M. H., Leach, M., Tomlinson, G. (2005): Examining the 
location and cause of death within 30 days of radical prostatectomy. BJU Int, 95, 541–544. 
Acknowledgement.  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
74 
 
ACKNOWLEDGEMENTS 
 
Firstly, I’d like to sincerely thank almighty ALLAH for all his grants that he bestowed on me. 
I would like to express my deepest gratitude to my advisor, Prof. Dr Klaus- Peter 
Jünemann, for the continuous support of my research, for his patience, motivation, and 
immense knowledge. His guidance helped me in all the time of research and writing of this 
thesis. I could not have imagined having a better advisor and mentor for my research. 
Besides my advisor, I would like to thank Dr. Osmonov, who as a good friend was always 
willing to help, give his best suggestions and provided me an opportunity to join his team, and 
who gave access research facilities. Without they precious support it would not be possible to 
conduct this research. 
I would like to take this opportunity to thank my colleagues in department of urology and 
pediatric Kiel University for their friendly attitude and the support they gave me when I 
needed it. 
I would like to pay special thankfulness, warmth and appreciation to all staff member in 
Urology department, Assuit University Hospital, Egypt, for their encouragement and 
support, which I learned a lot from you in my clinical and surgical skills.  
Warm thanks goes to my elderly sister Dr. Hala Abou Faddan, department of Public Health 
and Community Medicine, Assiut University, for her professional help in the statistical 
analysis of our data. 
I’d like to present my sincere thankfulness to my dear father and my deceased mother, who 
died September 2013, for their great role in my life and their numerous sacrifices for me and 
for my sisters and brother. Many thanks for my sisters Hala, Nagla and Eman and my 
brother Mohamed for their support, encouraging me with their best wishes and for being 
truly siblings when needed. 
Last but not least, I’d like to express my deepest gratitude to my beloved, my wife, Sally 
Hussein for her patience and tolerance over the last four years. Sally I could not be able to 
finish this work without your support. Thank you for being with me and for your appreciated 
sacrifices. 
 
 
Amr Abou Faddn                                                                                                                        2016 
   
57 
 
Curriculum vitae 
 
BIOGRAPHICAL:- 
 
First Name  Amr 
Last Name Abou Faddan 
Date of Birth 1982 
Place of Birth Saudi Arabia 
Citizenship Egyptian 
Marital Status Married 
Current Position Assistant lecturer, Urology Department, Faculty of 
Medicine Assiut University, Egypt. 
Email Amr.faddan123@gmail.com 
Research gat Amr Abou Faddan 
 
EDUCATION: 
 
1996 – 1999 High School Diplom 
Naser military school, Assuit , Egypt 
2000 – 2005 M.B. B.ch (M.D. degree)  
Assiut Faculty of Medicine, Assiut University Hospital, 
Assiut 71516, Egypt 
2007 – 2010 M.Sc. Female & Neuro urology, Review title (Female 
Sexual Dysfunction), Faculty of Medicine, Assiut 
University Hospital, Egypt. 
June 2011 
 
ICDL International computer Driving License at Assuit 
university network 
ACADEMIC POSITIONS: 
 
2006 – 2007 Intern, Rotation through the following departments: 
General Medicine, General Surgery, Obstetrics & 
Gynecology, Pediatrics. Anesthesia, Emergency room & 
Urology. Assiut University Hospital, Assiut 71516, Egypt 
2007 – 2010 Resident, General Urology, Department of Urology, Assiut 
University Hospital, Assiut 71516, Egypt 
March 2010 Instructor, Department of Urology, Faculty of Medicine, 
Assiut University, Egypt. 
Oct. 2010 Assistant Lecturer, Department of Urology, Assiut 
University, Faculty of Medicine, Egypt.  
April 2014 – Sept. 2014 DAAD scholarship and trainee research assistant at the 
Department of Urology of the University Hospital Halle 
Saale. 
Oct. 2014 to March 
2016 
DAAD scholarship, visiting doctor and researcher and 
doctoral student at the Department of Urology at the 
University Hospital Schleswig Holstein, Campus Kiel. 
 
  
Amr Abou Faddn                                                                                                                        2016 
   
57 
 
EXPERTISE: 
 
Specializes in Diseases and Conditions: 
1. Laparoscopic surgery. 
2. Uro-oncology. 
3. Voiding dysfunction 
4. Urinary incontinence and Urodynamics. 
5. Stones and Endourology: 
a. Renal: PNL, ESWL,  
b. Ureteral: URS, flexible URS and lithotripsy 
c. Bladder: cystoscopy and litholapaxy. 
6. Renal Ultrasonography. 
7. Andrology (Penile prosthesis ; semi-rigid and inflatable) 
 
HONORS 
MD Graduation title: Excellent with honor.2005 (ranking 12
th
 amidst my 
college): 
Msc Title: very good: 2010 
 
PAPLICATION: 
1- Shalaby MM, Faddan AA, Khalil M, Abdelhafez MF. April 2014. The 
management of the persistent Müllerian duct syndrome. Arab J Urol.  
2- Faddan AA, Jünemann KP, Osmonov DK. In press. Semi-rigid penile prosthesis 
as salvage management of idiopathic ischemic stuttering priapism. Res Rep Urol. 
3- Faddan AA, Jünemann KP, Osmonov DK. February 2016. Benchmarks for 
Partial Segmental Thrombosis of the Corpus Cavernosum: A Case Report and 
Review of the Literature.  
4- Osmonov DK, , Naumann CM, Hamann MF, Faddan AA, Jünemann KP. 
September 2016. Cancer-specific and overall survival in patients with recurrent 
prostate cancer who underwent salvage extended pelvic lymph node dissection. 
TRAINING PROGRAMS FOR DEVELOPMENT MY CAREER  
 
 International Publishing of Research training program at Faculty and Leadership 
Development Center, Assuit University, 10
th
 – 12th April, 2010. 
 Strategic Planning training program at Faculty and Leadership Development 
Center, Assuit University, 17
th
 – 19th April, 2010. 
 Conference Organization training program at Faculty and Leadership 
Development Center, Assuit University, 26
th
 – 28 th April, 2010. 
 How to Compete for a Research Fund training program at  Faculty and 
Leadership Development Center, Assuit University, 15
th
 – 17th May, 2010. 
 Student Evaluation training program at Faculty and Leadership Development 
Center, Assuit University, 22
th
 – 24th May, 2010. 
 Effective presentation training program at Faculty and Leadership Development 
Center, Assuit University, 12
th
 – 14th June, 2010. 
 
